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1. INTRODUCTION 
Medicinal chemistry concerns with the discovery, development, identification 
and interpretation of the mode of biologically active compounds at the molecular 
level.           
 Medicinal chemistry also concerned with the study, identification and 
synthesis of the metabolic products of drugs and related compounds.  The primary 
function of medicinal chemists is to discover new drugs, but knowledge of the 
underlying principles of biochemical action should be immense value for the design 
of new drug molecules.  The development of drug therapy could not progress until 
knowledge of anatomy and physiology had reached the status of science.  
The current trend in the drug design is to develop new clinically effective 
agents through the structural modification of a lead moiety.  The lead moiety is a new 
active compound which is typically found by screening many compounds for the 
desired biological properties. These lead can come from natural sources, such as 
plants, animals etc., more often it can come from synthetic sources such as historical 
compound collections and combinational chemistry. 
Once a lead compound has been discovered for a particular therapeutic use, 
the next step is to optimize the lead compound. An important method of lead 
optimization is optimization by bioisosterism.  Bioisosters are substituted group that 
have similar physical and chemical properties and hence similar biological activity 
patterns.  Bioisosteric replacement may help to decrease toxicity or to change the 
pharmacokinetic profile. 
The final step involves the rendering of lead compounds suitable for use in 
clinical trials.  This involves the optimization of synthetic route for bulk production 
and the preparation of compounds suitable for drug formulation.  
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1.1) 1, 3 – Benzothiazoles:  
A number of heterocyclic derivatives containing nitrogen and sulphur atom 
serve as a unique and versatile scaffolds for experimental drug design. Benzothiazole 
is one of the most important heterocycle that has received overwhelming response 
owing to its diversified molecular design and remarkable optical, liquid and electronic 
properties. Benzothiazole consists of thiazole ring fused with benzene ring and 
possess multiple applications. 
S
N
1
2
34
5
6
7
N
S
Thiazole 1,3 Benzothiazole
  
Thiazole is structurally related to thiophene and pyridine, but in most of its 
properties it resembles the latter.  Thiazole was first described by Hantzsch and 
Waber in 1887. Popp confirmed its structure in 1889. The numbering in thiazole starts 
from the sulphur atom.  The basic structure of 1, 3 benzothiazole consist of benzene 
ring fused with 4, 5-position of thiazole.  The two rings together constitute the basic 
nucleus 1, 3-benzothiazole.  
Molecular Formula : C7H5NS  
Molecular Weight :  135.19 
Physical and Chemical Properties of 1, 3 - Benzothiazole: 
(Anonymous http:// www.wikipedia.org) 
Description  :  Yellow liquid with unpleasant odour  
Boiling Point  :  227 - 228° C  
Melting Point  : 36° F (or) 2.00° C @ 760.00mm Hg 
Flash Point  :  >230.00° F  
3 
 
Density  :  1.238 g/ml at 25° C 
Refractive Index :  n20/D 1.642(lit) 
Vapor Pressure : 34 mm Hg at 131° C 
Vapor Density  : 4.66 (vs air)   
Solubility  :  Slightly soluble in water; very soluble in ethanol,  
diethyl ether and carbon disulfide; soluble in acetone 
Reactivity  :  Reacts with aldehydes or ketones to generate ahydroxy  
     carbonyl compounds  
Storage   : Stable (Regarded as highly persistent in the environment. 
Incompatible with strong oxidizing agent) 
The compounds encompassing benzothiazole moiety are of great interest and 
have been extensively used in pharmaceutical chemistry and agriculture division. 
Heterocycles bearing a benzothiazole ring residue are reported to show antimicrobial, 
anti-cancer, anti-inflammatory, analgesic, muscle-relaxant, sedative, anti-tubercular, 
diuretic, anticonvulsant, anti-allergic, anti-malarial, antiviral, anti-HIV, antioxidant, 
CNS depressant, anti-psychotic, schictosomicidal, anti-diabetic and plant growth 
regulatory activity etc. In addition, benzothiazole forms an important pharmacaphore 
in fungicidal, herbicidal and insecticidal, agents. (Priyanka et al., 2010) 
Different substitutions on benzothiazole moiety on different position are found 
to posses different activity, for example if substitution on 2 position on benzothiazole 
by any phenyl ring are used as an anticancer drug, if substitution on 2,5,6 position is 
used as anti-inflammatory agent. Substitution of phenyl imidazole ring used as an 
anthelmintic activity. Substitution of 4-acetamidophenyl sulphonamide on 2 position 
used as anti-tubercular activity. Substitution of 4-aminophenylsulphonamide on 2 
position and halo compounds on 6 position are used as anticonvulsant activity. 
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Substitution on 2 position by 4-aminophenyl and on 6 position by methoxy group 
used in Alzheimer’s disease. 
General Methods For The Synthesis of 1,3-benzothiazole:  
(Sukhbir L Khokra et al., 2011) 
1. Condensation of o-aminothiophenol with aldehydes: 
Treatment of o-aminothiophenols with substituted aldehydes affords the 
synthesis of 2-substituted benzothiazoles using different catalysts and reaction 
conditions. 
Catalysts (a-f):  
a. Montmorillonite, SiO2/Graphite; Microwave, p-TsOH 
b. Diethyl bromophosphonate/tert-Butyl hypochlorite; acetonitrile 
c. Cerium (IV) ammonium nitrate 
d. H2O2/HCl system in ethanol 
e. AcOH/Air; Microwave/ Thermal Heating  
f. Baker’s yeast, Dichloro methane  
 
SH
NH2
S
N
R
Catalysts (a to f)
R - CHO+
 
2. Condensation of o-aminothiophenol with acids: 
Treatment of o-aminothiophenols and substituted aromatic acids in the 
presence of polyphosphoric acid provides a good method to synthesis of 2-substituted 
benzothiazoles and gives good yield. 
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SH
NH2
S
N
R
Polyphosphoric acid
R - COOH +
 
3. Cyclization of Thioformanilides Using Different Reagent: 
Substituted thioformanilides can be converted to 2-aminobenzothiazoles via 
intramolecular C-S bond formation/C-H functionalization utilizing various reagents 
and catalysts.          
Catalysts (a-e):  
a. CuI; 1, 10-Phenanthroline, CS2CO3, reflux  
b. Manganese triacetate 
c. CS2CO3, Dioxane 
d. Photochemical cyclization induced by chloranil 
e. Pd (PPh3)4/MnO2 system under an oxygen atmosphere  
X
NH R
S
Z Catalysts (a to e) S
N
R
Z
 
4. Coupling Between Thiophenols and Aromatic Nitriles: 
Thiophenols when treated with aromatic nitriles to affords a smooth reaction 
mediated by ceric ammonium nitrate to give corresponding 2-arylbenzothiazoles in 
excellent yield. 
 
SH
R
1
R
2
CN
R
3
R
4
+ CAN (2equi). NaHCO3
MeCN, RT, 0.5 h
S
N
R
4
R
1
R
2
R
3
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5. Synthesis Using Anilines: 
Different substituted anilines when treated with potassium thiocynate in 
presence of glacial acetic acid to synthesize 2-substituted benzothiazoles. 
NH2
R
NH2
NCS
R
S
N
NH2RKCN/Br2/H2O
HCl/H2O
 
Fluorine in Bioactive Molecules: 
The incorporation of fluorine in drug molecule as a mean of increasing therapeutic 
efficacy is based on several considerations,  
1. Fluorine, the second smallest substituent, closely mimics hydrogen with 
respect to steric requirements at enzyme receptor sites (Vander waal’s radii 
F=1.35Aº; H=1.2Aº) 
2. The strong electron withdrawing inductive effect of fluorine can significantly 
influence reactivity and stability of functional groups and the reactivity of 
neighboring reaction centers. 
3. The substitution of hydrogen by fluorine at or near a reactive site frequently 
causes inhibition of metabolism because of the high C-F bond energy. 
4. The replacement of hydrogen by fluorine usually increases lipid solubility, 
thereby enhancing the rate of absorption and transport of drug in vivo. 
5. Some time the presence of fluorine instead of hydrogen actually blocks an 
essential biochemical reaction: the fluorine behaves as a receptor group                
Eg. 5- fluorouracil. 
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1.2) 1, 3, 4-Thiadiazole  
1, 3, 4-Thiadiazole is a isomer of thiadiazole series. It is a versatile moiety that 
exhibits a wide variety of biological activities.  They act as “hydrogen binding 
domain” and “two-electron donor system”.  It also acts as a constrained 
pharmacophore.  
1, 3, 4-thiadiazole are sulfur containing aromatic heterocycle with nitrogen 
atoms at the 3 and 4 positions and are numbered as shown below.  
 
 
The C-N bond length in 1,3,4-thiadiazole is very close to that in thiazole and 
the C-S bond length is nearly similar to that in thiophene. The N-N bond in 1,3,4-
thiadiazole also acquires some double bond character. The bond lengths in 1,3,4-
thiadiazole reflect that the single bonds acquire double bond character while double 
bonds acquire some single bond character and therefore suggest larger delocalization 
of π-electrons in 1,3,4-thiadiazole. 
1,3,4-Thiadiazole exists in two partially reduced  (dihydro) forms named as 
1,3,4-thiadiazolines depending on the position of the double bond. The completely 
reduced (tetrahydro) 1,3,4-thiadiazole is known as 1,3,4-thiazolidine. 
 
 
 
 
N N
S
1
2
3 4
5
1,3,4 Thiadiazole
S
N N
H
S
N N
S
N
H
N
H
1,3,4 - thiadiazolines 1,3,4 - thiazolidine
(dihydroforms) (tetrahydroform)
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Molecular Formula : C2H2N2S  
Molecular Weight :  86.11 
1,3,4-Thiadiazole is a versatile pharmacophore which exhibits a wide variety 
of biological activities like anti-microbial, anti-tubercular, anti-tumor, anti-
inflammatory, anti-hypertensive, anti-convulsant, anti-diabetic, anti-viral, 
anthelmintic, diuretic, anti-depressants, antioxidants, analgesic, oxidative inhibitors, 
anti H-pylori, hepatoprotective, anti-mycotic, cardiotonic etc.  
(Barve Ashutosh et al., 2009) 
General Methods For The Synthesis of 1,3,4-Thiadiazole: 
1. From Thiosemicarbazides:       
This is the most common method to synthesize 5-substituted 2-amino-1,3,4-
thiadiazoles which involves acyclation of thiosemicarbazide followed by dehydrative 
cyclization using any of the below mentioned agents sulfuric acid, phosphorus 
oxychloride, polyphosphoric acid, phosphorus halides or more recently methane 
sulfonic acid.  
NH
S
NH NH2R
(R
1
CO)2O NH NH
S O R
1
RHN
N N
SH OH
R
1
RHN-H2O
NN
SRHN R
1
 
However, 2-amino-1,3,4-thiadiazole is obtained by heating 
thiosemicarbazide with a mixture of formic acid and hydrochloric acid. 
R NH
S
NH NH2
N N
S NH2
HCOOH / HCl
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2. From Dimethylformamaide:    
 The reaction of N,N-dimethylformamide with thionyl chloride produces 
formamidoyl chloride which on treatment with N,N-diformylhydrazine and with 
sodium ethoxide gives a free base. The free base obtained undergoes cyclization in the 
presence of hydrogen sulfide with the formation of parent 1,3,4-thiadiazole. 
(H3C)2N CHO SOCl2 -SO2
N
+
CH3
CH3
Cl
Cl
-
(i) OHC-NH-NH-CHO
(ii) C2H5ONa
N(CH3)2
N N
N(CH3)2
H2SN N
S
+
 
3. From Hydrazine: 
 This is the one pot-synthesis of 2,5-dialkyl-1,3,4-thiadiazoles and involves the 
reaction of hydrazine with aldehyde and elemental sulfur. The reaction proceeds via 
an intermediate which is subsequently cyclized to 2,5-dialkyl-1,3,4-thiadiazole with 
the evolution of hydrogen sulfide involving the formation of C-S bond. 
NH2 NH2.H2O + O
H
R
+
O
H
R
+ SH2
N N
SH
R
SH
R
N N
S RR  
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S
N
NH2
O
CH3
Riluzole (Anti-Epileptic drug)
S
NOCH3
S
O
O
NH2
S
N
NH2
NH
CH3 O N
+
N
F
OH
S
N
CH3
S
N
N
CH3
CH3O
NCH3
CH3
S N
N
N
N
O
O
Ethoxzolamide (Diuretic)
Pramipexole (Anti-Depressants) Sabeluzole (Anti-Fungal)
Dimazole (Anti-Fungal)
Tiospirone (Anti-Psychotic drug)
S
N P
O
O O
CH3
CH3
S
N
NH
N
N
N
CH3
CH3
Fostedil (Anti-Hypertensive agent) Talarozole (To treat acne & psoriasis)
S
N
NH2
NH
CH3
Dexpramipexole (Anti-Epileptic)
S
+
N
CH3
S
N
CH3
Dithiazanine Iodide (Anthelmintic)
 
Fig-1: Compounds Containing 1, 3 - Benzothiazole Nucleus 
11 
 
N N
S NHCOCH3H2O2NS
Acetazolamide (Diuretic)
N
S
N N
O
O
N
H CH3
CH3
CH3
OH
Timolol (b-adrenergic blocker)
NN
SNNH
CH3
CH3
CH3
CH3
CH3
O
Tebuthiuron (Herbicides)
S
O
O
NH N
S
N
O
CH3
NH2
Sulfametrole (Anti-bacterial)
N
CH3
N
S
N
O
CH3
N
CH3
N
S
N
S
CH3
Xanomeline (M5 receptor antagonist) Tazomeline (Muscarnic ACH receptor agonist)
Vedaclidine (Analgesic)
N
S
N
S
CH3
N
S
N NCH3
CH3
O O O
CH3
CH3
Atibeprone (Anti-depressant)
N N
S S N
S
OH O
CH3 O
NH N
O
H
N
N
N
Cefazolin (Antibiotic)
NN
S
CH3
S N
S NH N
O
OH
Cl
O
O
OOH
H
Cefazedone (Antibiotic)
 
Fig-2: Compounds Containing 1, 3, 4 - Thiadiazole Nucleus 
 
  
 
 
LITERATURE REVIEW 
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2. LITERATURE REVIEW 
2.1 Literature Review For 1, 3 Benzothiazole 
2.1.1) Bobade AS et al., (2010) synthesized some phenyl thioureido sulfonamide 
benzothiazoles (Fig-3). These compounds were evaluated for their anti-bacterial and 
anti-fungal activity against gram positive Staphylococcus aureus (ATTCC 3750), 
gram negative Salmonella typhi (NCTC 786) and fungal strain Candida albicans.  It 
was observed that the electron donating moieties attached to the benzothiazole 
nucleus proved to be more potent than the electron withdrawing moieties. Among all 
the compounds tested methyl substituted benzothiazole (Va) showed highest potency 
against all three pathogenic strains. Although comparatively electron withdrawing 
moieties did not show good activity one of the derivatives (Vi) was relatively potent 
against all three pathogenic strains.  This may be due to the presence of two fluorine 
moieties present on the benzothiazole ring. 
 
 
Fig-3 
 
 
 
2.1.2) Velingkari VS et al., (2010) synthesized series of substituted 2-amino 
benzothiazoles (Fig-4). The compounds were confirmed by Thin Layer 
Chromatography and spectroscopic methods like UV, IR, 1H NMR and Mass. In 
addition the elemental analysis (Thermo Finnigan) was carried out manually by 
combustion method.  The synthesized compounds were screened for their in vitro 
anti-inflammatory activity. 
Code R R1 
Va 6 – CH3 H 
Vi 4F, 6F H 
N
S
NH S
O
O
NH
SCH3
NH
R R
1
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                       Fig-4 
2.1.3) Bhanushali MD et al., (2010) synthesized a series of various substituted 
benzothiazole derivatives containing 7-chloro-6-fluro-N (substituted hydrozones) – 
benzothiazole (Fig-5).  All the compounds were tested for their purity by TLC and 
melting point.  The structures of these compounds were confirmed by IR, NMR, and 
CNH analysis.  All these were found to be satisfactory.  The selected synthesized 
compounds MIIIC, MIIIF and MIIIJ were evaluated for anti-inflammatory activity by 
paw edema method using carragennan. The inflammation was measured by 
plethysmometer and synthesized compounds were given orally. There was significant 
reduction in the inflammation and compound MIIIJ has shown more significant anti-
inflammatory activity. 
 
 
 
Fig-5 
 
 
 
2.1.4) Nitendra K Sahu et al., (2011) synthesized a series of 1,3-benzothiazole-2-yl-
hydrazones and evaluated for antibacterial activity against four different bacterial 
species and antifungal activity against two different fungal species by disk diffusion 
method displaying different degree of antimicrobial activity. All the synthesized 
S.No. R 
1 p – toluidino 
2 Ethanol amino 
3 p – Hydroxy phenyl 
4 Dibutyl amino 
5 Diethyl amino 
Code Ortho Meta Para 
MIIIC H OCH3 OH 
MIIIF H NO2 H 
MIIIJ OCH3 OCH3 OCH3 
N
S
Cl
F
NH
N
R
N
S
NH
R
O
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compounds were in good agreement with elemental and spectral data (FT-IR, 1H 
NMR and Mass spectroscopy). In vitro antimicrobial activity was evaluated against 
the four pathogenic bacterial strains Bacillus subtilis, Escherichia coli, Klebsiella 
pneumoniae and Pseudomonas alkaligenes and three fungal strains Aspergillus niger, 
Rhizopus oryzae and Candida albicans. All the compounds have shown moderate 
activity. Compounds 3a (Fig-6) and 3b (Fig-7) were found to be most active. 
N
SNH
N
CH3
O2N
N
SNH
N
CH3
Br
 
Fig-6                Fig-7 
2.1.5) Balram Soni et al., (2011) synthesized a novel series of N-(1, 3-benzothiazol-
2-yl)-2-[(2Z)-2-(substituted arylidene) hydrazinyl] acetamide in order to determine 
their antimicrobial activities. The synthesized compounds were tested in vitro against 
two gram positive, one gram negative bacteria and two fungal strains in comparison 
with control drugs. Microbiological results showed that the synthesized compounds 
possessed a broad spectrum of antibacterial activity against the tested 
microorganisms. The compounds with a 4-amino group (Fig-8) and 4-dimethylamino 
group (Fig-9) on the aromatic ring possessing azomethine linkage showed better 
antimicrobial activity; almost similar to that of standard drugs thus they could be 
promising candidates for novel drugs. 
 
 
 
Fig-8 
 
N
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Fig-9 
2.1.6) Padmavathi P Prabhu et al., (2011) synthesized a series of Schiff’s base of 
several benzothiazole derivatives (Fig-10). The structure of synthesized compounds 
was characterized by IR, 1H NMR and Mass spectral data. Purity of the individual 
compound was confirmed by TLC. Then, each product was evaluated for their in vitro 
growth inhibiting activity against several microbes. All the compounds have shown 
significant antibacterial activity with the reference standard ampicillin and 
ketoconazole. 
 
 
 
Fig-10 
 
 
2.1.7) Priyanka Yadav et al., (2010) synthesized a series of novel 2-substituted 
hydrazino-6-fluoro-1,3-benzothiazole derivatives (Fig-11). The structures of few 
compounds were elucidated by IR and NMR. The efficacy of compounds was 
determined against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia 
coli, Pseudomonas aeruginosa for their microbiological activities. All the newly 
synthesized compounds showed good antimicrobial activity against Staphylococcus 
epidermidis (D1-D4), S.epidermidis (D2-D4), P.aeruginosa (D1-D3) and E.coli (D1 & 
D4). The compound D3 has better antimicrobial activity against S. aureus than other 
compounds. Compound D4 showed better activity against S.epidermidis and 
Code R 
P5a H 
P5b para- Cl 
P5c meta-F 
P5d para-NO2 
P5e para- OCH3 
P5f 4-F, 3-OCH3 
P5g para-CH3 
P5h para-OH 
S
N
OH
O
NR
N
S
NHCOCH2NH-N=CH N(CH3)2
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compound D2 showed better activity against P.aeruginosa whereas compound D1 
shows potent activity against E.coli. 
 
                               
 
 
Fig-11 
 
 
 
2.1.8) Venkatesh P et al., (2009) synthesized a series of some novel 2-amino 
benzothiazole derivatives and evaluated for anti-inflammatory activity (Fig-12). The 
compounds were synthesized from the substituted aromatic amines through the 
intermediate substituted 1-phenylthiourea oxidation by bromine water in acidic 
medium. The purity of the synthesized compounds was judged by their C, H and N 
analysis and the structure was analyzed on the basis of IR, 1H NMR and Mass spectral 
data. The anti-inflammatory activities of new compounds were determined by 
carrageenan-induced mice paw edema method using diclofenac sodium as a standard. 
Among the compounds tested three compounds Bt2 (5-chloro-1, 3-benzothiazole-2-
amine), Bt1 (6- ethoxy-1, 3-benzothiazole-2-amine) and Bt7 (6-methoxy-1, 3-
benzothiazole-2-amine) were the most active compounds in these series when 
compared with diclofenac sodium. In the SAR study, the phenyl ring substituted with 
chloro at 5 position, methoxy substitution at 4 and 6-position in benzothiazole ring 
system showed better anti-inflammatory activity. 
Code D1 D2 D3 D4 
R 
OCH3
OCH3
 OH
OH
 
F
 
OH
OH 
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                                         Fig-12 
2.1.9) Devmurari VP et al., (2010) synthesized a series of seven substituted 2-
phenyl-benzothiazole and substituted 1,3-benzothiazole-2-yl-4-carbothiaote 
derivatives. Substituted 2-phenyl-benzothiazole were synthesized by condensing 
substituted benzoic acid with 2-amino thiophenol in the presence of phosphoric acid 
and 3-benzothiazole-2-yl-4-substituted carbothiaote derivatives were prepared by 
condensing 2-mercaptobenzothiazole with substituted acid chloride. Structures of all 
the compounds were characterized by spectral and elemental analysis. All the 
synthesized novel compounds were screened for anticancer activity. It was also found 
that compounds 1, 2 (Fig-13) 6 (Fig-14) and 7 (Fig-15) showed very good anticancer 
activity whereas all the other compounds have showed mild to moderate anticancer 
activity when compared to standard drug. 
 
 
     
               
 
 
 
                        Fig-13 
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Code R 
Bt1 H 
Bt2 5-Cl 
Bt7 4-OCH3 
Compound R1 R2 R3 R4 
1 H H NH2 H 
2 F Cl Cl H 
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2.1.10) Sambhaji P Vartale et al., (2011) reported convenient and practical 
procedure for the synthesis of 10-methyl 14, 15-di-imino benzothiazolo[2,3-b] 
pyrimido [5,6-e] pyrimido [2,3-b] benzothiazole derivatives by using milder reaction 
conditions, simple workup with good yield. The structure of these newly synthesized 
compounds was established on the basis of elemental analysis, IR, NMR and Mass 
spectral data. Spectral studies of all compounds shows that compounds are stable & 
do not exhibit any tautomerism. All the newly synthesized compounds were tested for 
their antimicrobial activity using disc diffusion technique against S. aureus, B. 
Substilis, E. Coli and S. Typhi. The standard antibiotics norflaxacin showed zones of 
inhibition 14-24 mm, against bacterial strains. Among, all the newly synthesized 
compound 5h (Fig-16) show very good activity against B. Substilis whereas 
moderately active against S. Aureus, E. Coli and S. Typhi. 
N
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CH3
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NH NH
 
Fig-16 
 
2.1.11) Andrew D Westwell et al., (2006) synthesized a series of new 2-
phenylbenzothiazoles on the basis of the discovery of the potent and selective in vitro 
anti-tumor properties of 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole. Synthesis of 
analogues substituted in the benzothiazole ring was achieved via the reaction of o-
aminothiophenol disulfides with substituted benzaldehydes under reducing conditions. 
Compounds were evaluated in vitro in lung, colon, and breast cancer cell lines, 
compound 8n (Fig-17) was found to possess potent anti-proliferative activity. 
Structure-activity relationships established that the compound 8n stands on a pinnacle 
of potent activity, with most structural variations having a deactivating in vitro effect. 
19 
 
 
 
 
Fig-17 
2.1.12) Yaseen A Al-Soud et al., (2008) synthesized a series of benzothiazole bearing 
piperazino-arylsulfonamides (Fig-18) and arylthiol analogues (Fig-19) as well as 
substituted benzothiazoles having sulfonamides. All compounds were evaluated in 
vitro for their anti-proliferative activity against a large panel of human tumor-derived 
cell lines. Compounds 5c, 5d, 5j, 6b, 6c and 6j were the most potent analogues in this 
series, showing activity against both cell lines derived from haematological and solid 
tumors (CC 50range = 8-24 μM), only 5d was found to be selective and not cytotoxic 
to normal human tissues. 
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Code 6b 6c 6j 
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N
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2.1.13) Bhusari KP et al., (2009) synthesized some 4-amino-N-(1,3- benzothiazol-2-
yl) benzenesulphonamide derivatives and evaluated for in vitro anti-mycobacterial 
activity against H37Rv strain of Mycobacterium tuberculosis. Out of which the below 
mentioned compound (Fig-20) was found to have good anti-mycobacterial activity. 
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Fig-20 
 
2.1.14) Barot HK et al., (2010) synthesized nitrogen mustards of fluoro 
benzothiazoles and evaluated for their antibacterial and antifungal activity of against 
S. aureus, B. subtilis, C. tropicans, A. niger and F. heterosporium. The nitrogen 
mustards (Fig-21) and (Fig-22) showed excellent inhibition at a concentration of 50 
μg/ 0.1ml. 
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2.1.15) Patel NB et al., (2010) synthesized a new series of compounds 2-[(6-methyl-
1, 3- benzothiazol- 2- yl) amino]- N- [2- (substituted phenyl/ furan- 2- yl)- 4- oxo- 1, 
3- thiazolidin- 3-yl] nicotinamides (Fig 23 and 24) and examined to possess good        
in vitro antimicrobial activity against two gram positive (S. aureus and S. pyrogens), 
two gram negative (E. coli and P. aeruginosa) bacteria and three fungal species              
(C. albicans, A. niger, A. clvatus). 
N
N S
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NH
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R R
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N S
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N S
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                  Fig-23                                                          Fig-24   
R=H, 2-Cl, 2-NO2, 3-No2, 4-OH, 4-OMe,  R=H, 2-Cl, 2-NO2, 3-No2, 4-OH, 4-OMe,  
3-OMe-4-OH 3- OMe-4OH-5-NO2                3-OMe-4-OH, 3- OMe-4OH-5-NO2 and 
and 2-furyl      2-furyl 
 
2.1.16) Huang W et al., (2006) synthesized 2-(3, 4-difluoro-benzylsulfanyl)-4-fluoro 
benzothiazole (Fig-25) exhibited most interesting antifungal activities against R. 
22 
 
solani, B. cinereapers and D. gregaria among a series of polyfuorinated 2-
benzylthiobenzothiazoles. 
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2.1.17) Arun Pareek et al., (2010) synthesized some N-(4, 5-dihydro-1H-imidazol-2-
yl)-6-substituted-1,3-benzothiazol-2-amines and N-(1H benzimidazol- 2-yl)-6-
substituted-1,3-benzothiazol-2-amines. All the synthesized compounds were 
characterized by elemental analysis, IR spectra, 1H NMR and Mass spectral studies. 
They were screened for their anti-inflammatory, anti-ulcer, anti-tumor, entomological 
(anti-feedant, acaricidal, contact toxicity and stomach toxicity) and antibacterial 
activities. Among the synthesized compounds 3a (Fig-26) and 4a (Fig-27) compounds 
were found to possess good activity. The compounds also showed potent antiulcer, 
anti-inflammatory and antitumor. Antifeedant activity, contact toxicity and stomach 
toxicity tested against Spodoptera litura and acaricidal activity tested against 
Tetranychus urticae. 
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Fig-26       Fig-27 
 
2.1.18) Pattan SR et al., (2005) synthesized a series of 2-amino [5’(4-sulphonnyl 
benzylidine)-2-4- thiazolidinedione]-7-chloro-6-flurobenzothiazole and screened for 
their antidiabetic activity by alloxan induced tail tipping method on albino rats. All 
S
N
NH
Cl
N
NH
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the compounds showed good anti-diabetic activity and the below mentioned 
compound (Fig-28) showed maximum anti-diabetic activity.   
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                          Fig-28 
2.1.19) Pankaj Arora et al., (2010) synthesized various chromene -2- one derivatives 
and evaluated for antipsychotic activity. All the synthesized compounds showed 
antipsychotic activity with muscle relaxant property. The compound N-(fluoro 
benzothiazol-2-yl)-(4-Methyl-2-oxo-chromene-7-yloxy) (Fig-29) acetamide has been 
found to have significant atypical behavior. 
O
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2.1.20) Ghassoub Rima et al., (2009) reported the synthesis and characterization of 
new compounds derived from benzothiazoles and thiadiazoles. They observed that 
structural modifications on these skeletons affected the antioxidant activity. Thiol and 
aminothiol compounds derived from thiadiazoles and benzothiazoles showed an 
interesting antioxidant property. The radioprotective activity has also been evaluated 
in mice. In vivo tests showed an efficient radioprotective effect at LD99.9/30days-IRR for 
Code R 
1 H 
2 meta- NO2 
3 para-COOH 
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the compounds 4a (Fig-30) and 5a (Fig-31) and particularly for 2-mercapto-6-
methylbenzothiazole 4b (Fig-32) compared to WR-272. 
N
S
SH
H  
   Fig-30      Fig-31 
N
S
SH
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Fig-32 
 
2.2 Literature Review For 1,3,4-Thiadiazole 
2.2.1) Weerasak Samee et al., (2011) synthesized a series of 2,5-dimercapto-1,3,4-
thiadiazole (Fig-33) derivatives by nucleophilic substitution reaction. The cytotoxic 
activity was determined by green fluorescent protein (GFP)-based assay and anti-
candida activity was determined by Resazurin Microplate Assay (REMA). 
Compounds 1, 2 and 3 showed in vitro cytotoxic activities against Vero cells (African 
green monkey kidney). Compounds 1 and 4 exhibited anti-candida activities against 
Candida albicans (ATCC 90028) with IC50 values of 1.94 and 19.10 μg/ml, 
respectively. Docking studies on the catalytic site of cytochrome P450 14a-
demethylase were used to identify the chemical structures in the molecule responsible 
for cytotoxic and anti-candida activities of the synthesized compounds. 
 
N N
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Fig-33 
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2.2.2) Dhanya Sunil et al., (2009) synthesized a series of 3,6-disubstituted 1,2,4–
triazolo[3,4-b]-1,3,4-thiadiazoles were synthesized from 3-substituted-4-amino-5-
mercapto-1,2,4-triazoles and 3-substituted 4-carboxypyrazoles. Elemental analyses, 
IR, 1H NMR and Mass spectral data confirmed the structures of all newly synthesized 
compounds. Most of the newly synthesized compounds were screened for their 
anticancer activity in hepatic cell lines. Many of the compounds were found to be 
potent. The perturbations brought by the substituent can affect various parameters of 
the molecule like its electron density, its steric environment, its bioavailability etc. 
The thiadiazole with naphthyloxymethyl and fluorophenyl groups (Fig-34) as 
substituent’s showed (Fig-34) excellent anti-proliferative effect.  
N
N
H
N
NN
S
N
CHCH2
F
O
 
Fig-34 
2.2.3) Arvind Kumar Singh et al., (2011) synthesized some 2, 5 substituted 1,3,4- 
thiadiazoles (Fig-35). The structures of the synthesized compounds were confirmed 
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by IR, NMR, and Mass spectra data. The compounds were evaluated for antibacterial 
and anti-inflammatory activity. The anti-inflammatory activity was carried out by 
carrageenean induced paw oedema method using indomethacine as standard drug. 
Among all synthesized compounds 2 and 5 shown good anti-inflammatory activity. 
Whereas all the synthesized compounds shown moderate antimicrobial activity 
against S. aureus, E. coli, and A. niger. 
 
N N
S CH3
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Fig-35 
 
2.2.4) Himaja M et al., (2011) synthesized some 2-amino-5-aryl-5H-thiazole [4, 3-
b]-1,3,4-thiadiazoles (Fig-36) by using aromatic aldehydes, thioglycolic acid and 
thiosemicarbazide. Structures of all synthesized compounds were confirmed by FT-
IR, 1H NMR and Mass spectral data. Their anti-tubercular activity was studied.  All 
the synthesized compounds have shown good anti-tubercular activity. 
 
 
 
 
Fig-36 
 
 
2.2.5) Barve Ashutosh et al., (2009) synthesized a series of 1,3,4-thiadiazol-2-amine 
(Fig-37). The structures of the compounds were confirmed by IR, NMR and Mass 
S.No. R 
1 C6H5 
2 2-C6H4Cl 
3 3-C6H4Cl 
4 4-C6H4Cl 
5 2-C6H4NO2 
6 3-C6H4NO2 
7 4-C6H4NO2 
S.No. R 
1 Ph 
2 4-MeC6H4 
3 4-HOC6H4 
4 4-HOC6H4 
5 4-O2C6H4 
6 4-Me2NC6H4 
7 2-ClC6H4 
8 2,4-Cl2C6H3 
S
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S
R
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spectral analysis. The newly synthesized compounds were evaluated for the 
antibacterial and antifungal activity. The results show that compound a, e, f, and h 
exhibit moderate to good antibacterial and antifungal activity at 5-100mcg/ ml.  
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                    Fig-37 
 
2.2.6) Shiv K Gupta et al., (2011) synthesized a new series of 5-(o-hydroxy phenyl)-
2-[4’aryl-3’chloro-2’azetidinon-1-yl]-1,3,4-thiadiazoleand the structures of the new 
compounds were established on the basis of IR, 1H NMR spectral data. In vitro 
antifungal activity (MIC activity) was evaluated and compared with standard drug of 
ketoconazole. The below mentioned compound (Fig-38) has shown interesting 
antifungal activity against both C. albicans and A. niger fungus. In the gratifying 
result, most of the compounds were found to have moderate antifungal activity.  
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Fig-38 
2.2.7) Nandini R Pai et al., (2010) synthesized some novel aryloxy propanoyl 
thiadiazoles (Fig-39) as potential anti-hypertensive agents based on structure activity 
relationship with propanalol. The structure of the compounds was confirmed on the 
basis of both analytical and spectroscopic data. The synthesized compounds are 
mentioned below. 
Compound 
 a=n=1 Malonic acid 
e=n=5 Pimelic acid 
f=n=6 Suberic acid 
h=n=8 sebacic acid 
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2.2.8) Foroumadi A et al., (2007) synthesized several novel 2-amino-5-[4-chloro-2-
(2-chlorophenoxy)phenyl]-1,3,4-thiadiazole derivatives and the anticonvulsant 
activity was determined by evaluation of the ability of these compounds to protect 
mice against convulsion induced by a lethal doses of pentylentetrazole (PTZ) and 
maximal electroshock (MES). The result of anticonvulsant data shows that among the 
synthesized compounds, 5-[4-chloro-2-(2-chlorophenoxy) phenyl]-N-ethyl-1,3,4-
thiadiazol-2-amine (Fig-40)  was the most active compound in both MES and PTZ 
tests with an ED50 of 20.11 and 35.33 mg/kg, respectively.  
S.No. R Ar- 
1 -CH3 
 
2 -CH3 
 
3 -CH2CH3 
 
4 -CH2CH3 
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2.2.9) Sudhir Bharadwaj et al., (2011) synthesized some 4-(substituted 
benzylidene)-1-(5-mercapto-1,3,4-thiadiazol-2-yl) -2-phenyl-1H-imidazol-5(4H)-one 
(Fig-41)  by using microwave irradiation method and confirmed the structure of all 
the compounds by elemental analysis and spectral analysis (1H NMR, IR and Mass). 
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2.2.10) Bijo Mathew et al., (2010) synthesized some Schiff bases of 1, 3, 4 
thiadiazole derivatives and evaluated for anthelmintic activity. The structures of the 
compounds were confirmed by IR, 1H NMR and elemental analysis. The 
physicochemical properties involve determination of drug-like property of the 
synthesized compounds. It is based on the Lipinski’s rule of 5 and can be determined 
by using molinspiration cheminformatics software. All the synthesized compounds 
showed zero violation of Lipinski’s rule of five, which indicates good bioactivity and 
S.No. R 
1 H 
2 4-F 
3 4-Cl 
4 2-Cl 
5 4-NO2 
6 3-NO2 
7 4-OH 
8 4-OH 
9 4-OCH3 
10 4-N(CH3)2 
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bioavailability. The anthelmintic activity of those compounds was investigated by 
method described in details by Kuppast and Nayak. Parameter under study was mean 
paralysis and mean lethal time in Pheretima posthuma. The below mentioned 
compounds (Fig-42) produce good anthelmintic activity. 
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2.2.11) Byran Gowramma et al., (2011) synthesized a series of 1, 3, 4-thiadiazole 
derivatives (Fig-43). The structures of the compounds were established by means of 
IR, 1H NMR and Mass spectrum analysis. All the compounds were evaluated for 
antibacterial and antifungal activities. Most of the compounds have shown significant 
antibacterial and antifungal activity when compared with the standard drugs. 
S
NN
Ar
-
NHCH2R 
Fig-43 
R = C6H6N & C6H5NCl  
Ar = C6H5, C6H4OH, C6H4N(CH3)2, C6H4OH, C6H4Cl, C6H4NO2 & C4H3S 
S.No. R1 R2 R3 R4 R5 
1 OH H H H Cl 
2 OH NO2 NO2 H Cl 
3 OCOCH3 NO2 NO2 H Cl 
4 H H H H H 
5 H NO2 H H Cl 
6 H NO2 H OH H 
7 H NO2 H H H 
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2.2.12) Foroumadi A et al., (2007) synthesised some novel 2-(nitroaryl)-5-
(nitrobenzylsulfinyl and sulfonyl)-1,3,4-thiadiazole derivatives and evaluated for their 
anti-tuberculosis activity. QSAR studies were subsequently used to find the structural 
requirements for activity of this series of compounds. It was concluded that the below 
mentioned compound (Fig-44) was the anti-mycobacterial agents showing MIC value 
of 6.25 μg.ml-1. The results of QSAR study demonstrated that electronic distribution 
is among the most important determining factors for activity in this series of 
compounds. 
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2.2.13) Mohammad Asif et al., (2009) designed, synthesized and investigated the     
in vivo anti-inflammatory activity of some 2,4-disubstituted-5-imino1, 3, 4-thiadiazole 
derivatives. The below mentioned compound IIIg (Fig-45), (2-p-aminophenyl-4-
phenyl-5-imino-Δ2-1, 3, 4-thiadiazole) exhibited highest anti-inflammatory activity  
(P <0.0001) with a percentage inhibition of 35.5. It was concluded that the thiadiazole 
compounds can potentially be developed into useful anti-inflammatory agents.  
 
 
 
 
Fig-45 
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2.2.14) Mahmoud M M Ramiz et al., (2011) synthesized a number of new 2,5-
disubstituted 1,3,4-thiadiazole and their S- or N-substituted derivatives as well as the 
corresponding sugar hydrazone and tested them for their antimicrobial activity against 
Bacillus subtilis (gram positive), Pseudomonas aeruginosa (gram negative), and 
Streptomyces species (Actinomycetes). The results revealed that compound 9 (Fig-46) 
showed the highest inhibition activity against Pseudomonas aeruginosa, whereas 
compound 6 (Fig-47) were the most active among the series of tested compounds 
against Streptomyces species with MIC values of 75 μg/mL. 
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   Fig-46      Fig-47 
 
2.2.15) Brijendra Kumar Soni et al., (2011) synthesized 1,3,4-thiadiazole 
derivatives (Fig-48) and were investigated for their in vitro antioxidant activity. The 
results revealed that, some of tested compounds showed potent antioxidant activity. 
Among all the compounds, compound 1 has shown good activity. While the 
compound 2 has shown moderate activity.  
 
 
 
 
           Fig-48 
 
2.2.16) Parmar Kokila et al., (2011) synthesized some new and biologically active 
[1,2,4] triazolo [3,4-b][1,3,4] thiadiazole-2-aryl-thiazolidinone-4-ones by reaction of 
S.No. R 
1 4-OCH3-C6H4- 
2 2-Furyl 
N N
S
N
R
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Schiff bases with mercapto acetic acid in presence of THF with adding anhydrous 
ZnCl2. The structures of the synthesized compounds have been established on the 
bases of IR, PMR, CMR and elemental analysis. The compounds have been evaluated 
for antibacterial activity against B. subtilis, S. aureus, P. aeruginosa and E. coli. The 
compound 1, 2, 3 and 4 (Fig-49) were shown significant activities. 
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2.2.17) Mohammed N Al - Ahdal et al., (2009) synthesized some new 1,3,4 
thiadiazole analogs for the inhibition of growth of Leishmania donovani, the causative 
agent of visceral leishmaniasis, which is transmitted by sand flies and replicates 
intracellularly in their mammalian host cells. Fourty four 1,3,4-thiadiazole derivatives 
and related compounds were tested in vitro for possible anti-leishmanial activity 
against the promastigotes of L. donovani, out of which seven compounds were 
identified with potential antigrowth agents of the parasite. The below mention 
compound (Fig-50) was the most active compound at 50µM among all.  
 
 
 
 
 
 
 
 
Fig-50 
S.No. Ar 
1 4-OCH3-C6H5 
2 4-OH-C6H5 
3 2-OH-C6H5 
4 3-OC2H5-4-OC2H5-C6H4 
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2.2.18) Bahar Ahmed et al., (2008) synthesized a series of new imine derivatives of 
5–amino-1,3,4-thiadiazole and their anti-depressant activity was tested by using 
imipramine as reference drug. In present study two compounds (Fig-51 & 52) have 
shown significant anti-depressant activity, which decreased immobility time 
compared to the standard imipramine. All the compounds in the series have passed 
neurotoxicity tests. 
 
 
 
 
 
 
 
 
 
 
 
Fig-51          Fig-52 
R1 --- H; OCH3; (CH3)2N; Cl; OH.         R2 --- H; Cl. 
 
 
2.2.19) Alireza Foroumadi et al., (2005) synthesized a novel series of 1,3,4–
thiadiazole derivatives and evaluated for in vitro leishmanicidal activity against 
Leishmania major promastigotes. The leishmanicidal data discovered that compounds 
had strong and much better leishmanicidal activity than the reference drug pentostam. 
The compound piperizene (Fig-53) analog was most active compound. 
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Fig-53 
X --- CH2; O; NH; NMe; NPh; NCOMe; NCOPh. 
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2.2.20) Mohammed K Abdel-Hamid et al., (2007) synthesized a new series of 1,3,4-
thiadiazole derivatives (Fig-54 and 55) and assayed for the inhibition of three 
physiologically relevant carbonic anhydrase isozymes, the cytosolic human isozymes 
I and II, and the transmembrane. In addition, docking of the tested compounds into 
carbonic anhydrase II active site was performed in order to expect the affinity and 
orientation of these compounds at the isozyme active site. The results showed similar 
orientation of the target compounds at CA II active site compared with reported 
sulfonamide type CA I with the thione group acting as a zinc-binding moiety. 
 
 
 
 
. 
           Fig-54        Fig-55 
X --- H; Br; NO2; R --- H; CH3; C6H5.  
R1 --- C6H5;4-(OH)C6H4; 3-(OCH3)C6H4; 4-(OCH3)C6H4; 2-(Cl)C6H4;  
4-(Cl)C6H4; 3-(OCH3)-4-(OH)C6H3; 3-(Br)C6H4; 4-(Br)C6H4; 
4-(F)C6H4; 2-(NO2)C6H4; 4-(NO2)C6H4; 2-[N(CH3)2]C6H4; C6H5;  
4-(CH3)C6H5; 3-Pyridyl; 2-Furyl. 
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3. AIM AND PLAN OF WORK 
AIM 
Research for the development of new therapeutic agents is becoming the 
major interest in many academic and industrial research laboratories all over the 
world with the aim to discover newer, more potent molecules, with higher specificity 
and reduced toxicity than the existing ones. In addition, the various types of resistant 
microorganisms that are discovered now-a-days are becoming a great challenge for 
the scientists. 
 The existing drugs that are available are either very expensive or are prone to 
microbial resistance. Most of the drugs that are marketed today are modified 
derivatives of existing pharmacophores. No new pharmacophore having a novel 
mechanism of action has been identified in the recent past. To overcome these 
problems, it becomes necessary for further investigating newer molecules to treat 
infections at affordable costs.       
 Fluorine incorporated benzothiazole and 1,3,4 - thiadiazole derivatives are 
known  to possess a variety of physiological properties like anti-microbial, anti-
tubercular, anti-tumor, anti-inflammatory, anti-hypertensive, anti-convulsant, anti-
diabetic, anti-viral, anthelmintic, diuretic, anti-depressants, antioxidants, analgesic 
etc., It was felt interesting to bring these two biologically active moieties within a 
molecular frame work with a view to study their additive effect on biological 
properties.           
 With the dual aim of developing potential therapeutic agents and studying 
their chemistry we undertook the synthesis of biologically active fluorobenzothiazole 
incorporated with 1,3,4 - thiadiazole compounds for anti-bacterial and anti-
inflammatory activity with minimum toxic levels.  
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PLAN OF WORK 
1. Literature was collected on related benzothiazole and 1, 3, 4 - thiadiazole    
compounds. 
2. Synthesis of fluorobenzothiazole incorporated 1, 3, 4 - thiadiazole compounds 
by appropriate method as per literature. 
3. Characterization of the newly synthesized compounds by physical data such as 
 Colour and nature  
 Melting point  
 Solubility 
 Thin layer chromatography (Rf  value) 
 UV – Visible Spectroscopy 
4. Conformation of the structures of the synthesized compounds by  
 IR Spectroscopy 
 NMR Spectroscopy 
 Mass Spectroscopy 
5. Evaluation of antimicrobial activities for synthesized compounds (SH6 and 
SH11) by disc diffusion method.  
6. Evaluation of anti-inflammatory activity for the synthesized compounds (SH8 
and SH11) by carrageenan induced paw oedema method. 
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38 
 
4. EXPERIMENTAL 
4.1. Materials 
 
4.1.1. List of Chemicals and Drugs Used: 
 
S. No Name of Chemicals / Drugs Manufacture 
1 3-chloro-4-fluoro aniline Sisco Research Lab. Pvt. Ltd., Mumbai. 
2 2 – Furoic acid Central Drug House Pvt. Ltd., Chennai. 
3 2 – Nitro aniline Loba Chem. Pvt. Ltd., Mumbai. 
4 4 – Nitro aniline Loba Chem. Pvt. Ltd, Mumbai. 
5 Anthranilic acid Spectro Chem. Pvt. Ltd., Mumbai. 
6 Ammonia solution Loba Chem. Pvt. Ltd., Mumbai. 
7 Benzene Qualigens Fine Chem. Pvt. Ltd., Mumbai. 
8 Bromine Loba Chem. Pvt Ltd, Mumbai. 
9 Carbon disulphide Loba Chem. Pvt. Ltd., Mumbai. 
10 Chloroform Spectro Chem. Pvt. Ltd., Mumbai. 
11 Carrageenan  sodium Sigma Chemical Co. Ltd., USA 
12 Diclofenac sodium German Remedies Ltd., Mumbai. 
13 Dimethyl formamide Loba Chem. Pvt. Ltd., Mumbai. 
14 Ethanol Changshu Yangyuan Chemicals, China. 
15 Glacial acetic acid Qualigens Fine Chem. Pvt. Ltd., Mumbai. 
16 Hydrazine hydrate Loba Chem. Pvt. Ltd., Mumbai. 
17 Methanol Qualigens Fine Chem. Pvt. Ltd., Mumbai. 
18 Nicotinic acid Loba Chem. Pvt. Ltd., Mumbai. 
19 Phosphrous oxychloride Loba Chem. Pvt. Ltd., Mumbai. 
20 Potassium thiocyanate Loba Chem. Pvt. Ltd., Mumbai. 
21 Polyethylene glycol Spectro Chem. Pvt. Ltd., Mumbai. 
22 Sodium chloro acetate Himedia Laboratories Pvt. Ltd., Mumbai. 
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4.1.2. List of Instruments Used: 
S. No Name of Instrument Manufacture 
1 1H-NMR spectrophotometer JEOL JNM-α 400 spectrometer 
2 Digital electronic balance Shimadzu Ax - 200 
3 Double beam UV-spectrophotometer 
Shimadzu 1601 UV-Spectrophotometer, 
Japan. 
4 FT-IR spectrophotometer Perkin-Elmer and Fischer Nicolet Spectroscopy, 
5 Heating mantle Ajay, Thermo Electrics, Chennai 
6 Hot air oven Precision Scientific Co., Chennai. 
7 Mass spectrophotometer Jeol SX102/DA-6000 Mass Spectrometer 
8 Magnetic Stirrer Remi Equipments, Chennai. 
9 Melting point apparatus Elico Ltd., Hyderabad. 
10 Plethysmometer Inco Rat Paw Plethysmograph Mercury Model, Ambala, India. 
 
Analytical grade solvents and reagents were used throughout the experiment. All 
the glasswares of borosil A grade and were as oven or flame dried for moisture 
sensitive reactions. When necessary, solvents and reagents were dried prior to use. 
Solution or extracts in organic solvents were dried over anhydrous sodium sulphate or 
fused calcium chloride before evaporation to under vacuum using rotary evaporator. 
Analytical samples were dried in vaccum and were free of significant impurities on 
TLC. 
4.1.3. Microorganisms:        
 The gram positive bacteria (Micrococcus luteus NCTC 4635), gram negative 
bacteria (Proteus vulgaris NL98) and fungal strain (Aspergillus flavus ATCC 46646) 
were procured from Microbial Resources Division, Kings Institute of Preventive 
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Medicine, Guindy, Chennai. The agar medium was purchased from HI Media 
Laboratories Ltd., Mumbai, India. 
 4.1.4. Animals:         
 The animals (Wistar albino rats of either gender) were procured from the Kings 
Institute of Preventive Medicine, Guindy, Chennai. Animals were housed in animal 
house in Adhiparasakthi College of Pharmacy in standard environmental conditions of 
temperature (25 ± 20º C), humidity (55 ± 10%) and light (12 : 12 hour light: dark 
cycle). The animals were fasted prior to dosing but water was given ad-libitum. The 
anti-inflammatory activity was carried out as per CPCSEA (Committee for the 
Purpose of Control and Supervision of Experiments on Animals) guidelines after 
obtaining the approval from the Institutional Animal Ethical Committee. 
4.1.5. Analytical Techniques  
4.1.5.1. Physical Data: 
Melting points of the synthesized compounds were taken in open capillaries 
on Guna Enterprises melting point apparatus and are uncorrected. 
4.1.5.2. Thin Layer Chromatography (TLC): 
Purity of the compounds was checked by thin layer chromatography using 
silica gel G as stationary phase and various combinations of ethyl acetate and 
chloroform (2:1) mobile phase. The spots resolved were visualized in UV chamber or 
Iodine vapour. 
4.1.5.3. Instrumentation: 
The techniques employed for the characterization of the synthesized 
compounds were UV, IR spectra, 1H NMR spectra, Mass spectra. 
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UV spectra: 
The Ultra Violet Spectroscopy of the synthesized compounds was recorded on 
double beam UV spectrophotometer (SHIMADZU -1700) at Adhiparasakthi College 
of Pharmacy. 
Infrared Spectra: 
The IR spectra of the synthesized compounds were recorded on a Fourier 
Transform IR spectrometer (Perkin-Elmer and Fischer Nicolet) in the range of 4000 – 
450 cm-1 by KBr pellets technique. It was recorded at Indian Institute of Technology 
Madras, Chennai and Ideal Analytical and Research Institution, Puducherry. 
Nuclear Magnetic Resonance Spectra (1H NMR): 
1H NMR spectra were recorded at Sophisticated Analytical Instrumentation 
Facility, IITM, Chennai on (Bruker-NMR 400mHZ) spectrometer using DMSO-d6 as 
solvent and chemical shifts were reported in δ values using tetramethylsilane as 
internal standard with number of protons, multiplicities (s-singlet, d-doublet, t-triplet, 
m-multiplet).  
Mass Spectra: 
The mass spectrum of the synthesized compounds was recorded on Jeol 
SX102/DA-6000 apparatus at Sophisticated Analytical Instrumentation Facility, 
Indian Institute of Technology Madras, Chennai.  
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4.2 Methodology: 
 
Monitoring of Synthetic Reaction Procedures: 
Established synthetic procedures were employed for synthesis of compounds 
SH1 to SH11 and the reactions were monitored by Thin Layer Chromatography (TLC) 
employing 6’’ X 2’’ plates coated with 0.25 mm thick layer of silica gel (pre-
activation by heating at 110° C for one hour). Solvent systems of varying 
combinations of ethyl acetate and chloroform (2:1) mobile phase was used to 
monitor the reactions. The plates were visualized in UV chamber or Iodine vapour. 
Purification Techniques: 
Recrystallization: The crude products were recrystallized by charcoal 
treatment in appropriate solvent. Wherever possible combinations of solutions were 
used. 
Authentication of Chemical Structures and Purity of Compounds: 
Chemical structure of products and their purity were ascertained by thin layer 
chromatography, UV-Visible spectrometer, melting point and various spectral 
techniques including Ultra Violet Spectrophotometry, Fourier Transform Infra Red 
Spectroscopy, Nuclear Magnetic Resonance Spectroscopy, and Mass Spectroscopy. 
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4.3. Synthesis of Compounds: 
4.3.1 Synthesis of 2-amino-6-fluoro-7-chloro-(1,3)-benzothiazole: (SH1) 
Reaction: 
NH2
Cl
F
N
S
NH2
Cl
F
3-chloro-4-fluoro aniline SH1
KSCN / ACOH
Br2 / NH3 0oC
 
Procedure: 
To the glacial acetic acid (20 ml) which was cooled below room temperature, 
added 8 gm (0.08 mole) of potassium thiocyanate and 1.44 gm (0.01 mole) of 4-
flouro-3-chloro aniline. The mixture was placed in cold mixture of ice and salt and 
mechanically stirred. 1.6 ml of bromine in 6 ml of glacial acetic acid was added from 
a dropping funnel at such a rate that temperature never rose beyond 0º C. After all the 
bromine was added (105 minutes) the solution was stirred for 2 hours in ice cold 
condition and at room temperature for 10 hours. It was then allowed to stand 
overnight, during the period orange precipitate settled at the bottom, water (6 ml) was 
added quickly in it and slurry was heated to 85º C on a steam bath and filtered while 
hot. The orange residue was placed in a reaction flask and treated with 10 ml of 
glacial acetic acid heated again to 85º C on a steam bath and filtered hot. The 
combined filtrate was cooled and neutralized with concentrated ammonia solution up 
to pH-6. The precipitate was collected and recrystallized from benzene and ethanol 
(1:1) after treatment with charcoal gave yellow crystal of 2-amino-6-fluoro-7-chloro 
benzothiazole. (Bhushankumar S Sathe et al., 2011) 
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4.3.2 Synthesis of 6-fluoro-7-chloro-(1,3)-benzothiazole-2-thiosemicarbazide: (SH2) 
Reaction: 
N
S
Cl
F
NH2
SH1 SH2
NH3, CS2, NH2.NH2.H2O
Sodium Chloro Acetate
C2H5OH
N
S
NH
F
Cl
S
NH NH2
Procedure: 
    2-amino-6-fluoro-7-chloro benzothiazole (SH1) 20.1 gm (0.1mole) was 
dissolved in 50 ml of ethanol (95%) and 8 ml of ammonia solution was added to it. 
The reaction mixture was cooled below 30º C and 8 ml of carbon disulphide was 
added slowly within 15 minutes with continuous shaking. After complete addition of 
disulphide the solution was cooled to stand for 1 hour. Then 9.4 gm (0.1 mole) 
sodium chloro acetate was added to it. The reaction was exothermic. To it 20 ml of 
50% hydrazine hydrate was added. The mixture was warmed gently, filtered and 
boiled to half of its volume and kept overnight. Next day, the product 
thiosemicarbazide was filtered and recrystalised from ethanol.  
(Vedavathi M et al., 2010)  
4.3.3 Synthesis of 7-chloro-6-fluoro-N-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazol-2-amine: (SH3) 
Reaction: 
N
S
NH
F
Cl
S
NH NH2
SH2 SH3
Reflux 18-24 hrs
N
S
NH
F
Cl
S
NN
O
POCl3&
O
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Procedure:   
A mixture of 6-fluro-7-chloro-(1,3)-benzothiazole-2-thiosemicarbazide (0.01 
mole), 2 – furoic acid (0.1mole) and phosphrous oxychloride 25ml was refluxed for 
18 – 24 hours. The reaction mixture was cooled to the room temperature and was 
slowly poured in to crushed ice and kept overnight.  The solid separated was filtered, 
dried and recrystallized from methanol. (Senthil Kumar G P et al., 2011) 
4.3.4 Synthesis of 7-chloro-6-fluoro-N-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazol-2-amine: (SH4) 
Reaction: 
N
S
NH
F
Cl
S
NH NH2
SH2
SH4
POCl3
Reflux 18-24 hrs
N
S
NH
F
Cl
S
NN
N
N
&
Procedure:   
A mixture of 6-fluro-7-chloro-(1,3)-benzothiazole-2-thiosemicarbazide (0.01 
mole), nicotinic acid (0.1mole) and phosphrous oxychloride 25ml was refluxed for 18 
– 24 hours. The reaction mixture was cooled to the room temperature and was slowly 
poured in to crushed ice and kept overnight.  The solid separated was filtered, dried 
and recrystallized from methanol. (Senthil Kumar G P et al., 2011) 
4.3.5 Synthesis of 7-chloro-6-fluoro-N-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-yl]-
1-3-benzothiazol-2-amine: (SH5) 
Procedure:   
A mixture of 6-fluro-7-chloro-(1,3)-benzothiazole-2-thiosemicarbazide (0.01 
mole), anthranilic acid (0.1 mole) and phosphrous oxychloride 25 ml was refluxed for 
18 – 24 hours. The reaction mixture was cooled to the room temperature and was 
46 
 
slowly poured into crushed ice and kept overnight.  The solid separated was filtered, 
dried and recrystallized from methanol. (Senthil Kumar G P et al., 2011) 
Reaction: 
N
S
NH
F
Cl
S
NH NH2
SH2
N
S
NH
F
Cl
S
NN
NH2
Reflux 18-24 hrs
POCl3&
NH2
SH5
 
4.3.6 Synthesis of 6-fluoro-N2-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-N7-(2-
nitrophenyl)-1,3-benzothiazole-2,7-diamine: (SH6) 
Procedure: 
 0.0025 mole of 7-chloro-6-fluoro-N-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazol-2-amine  was treated with equimolar quantity (0.0025 mole) of 2 – nitro 
aniline was substituted and refluxed for 2 hours in the presence of DMF. The mixture 
was then cooled and poured in to crushed ice. The solid separated was filtered, dried 
and recrystallized from benzene and absolute alcohol (1:1).            
(Gupta Akhilesh et al., 2010) 
Reaction: 
SH6
N
S
NH
F
NH
S
NN
O
NO2
SH3
N
S
NH
F
Cl
S
NN
O NH2
NO2
DMF,Reflux 2 hrs
 
47 
 
4.3.7 Synthesis of N7-(2,4-dinitrophenyl)-6-fluoro-N2-[5-(furan-2-yl)-1,3,4-
thiadiazol-2-yl]-1,3-benzothiazole-2,7-diamine: (SH7) 
Procedure:  
0.0025 mole of 7-chloro-6-fluoro-N-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazol-2-amine was treated with equimolar quantity (0.0025 mole) of 4 – nitro 
aniline was substituted and refluxed for 2 hours in the presence of DMF. The mixture 
was then cooled and poured in to crushed ice. The solid separated was filtered, dried 
and recrystallized from benzene and absolute alcohol (1:1).  
(Gupta Akhilesh et al., 2010) 
SH7
N
S
NH
F
NH
S
NN
O
NO2
SH3
N
S
NH
F
Cl
S
NN
O NH2
NO2
DMF,Reflux 2 hrs
 
4.3.8 Synthesis of 6-fluoro-N7-(2-nitrophenyl)-N2-[5-(pyridin-3-yl)-1,3,4-
thiadiazol-2-yl]-1,3-benzothiazole-2,7-diamine:(SH8) 
Procedure: 
 0.0025 mole of 7-chloro-6-fluoro-N-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-
1,3-benzothiazol-2-amine was treated with equimolar quantity (0.0025 mole) of         
2 – nitro aniline was substituted and refluxed for 2 hours in the presence of DMF. The 
mixture was then cooled and poured in to crushed ice. The solid separated was 
filtered, dried and recrystallized from benzene and absolute alcohol (1:1).  
(Gupta Akhilesh et al., 2010) 
 
 
48 
 
Reaction: 
N
S
NH
F
NH
NO2
S
NN
N
SH4
NH2
NO2
DMF, Reflux 2 hrsN
S
NH
F
Cl
S
NN
N
SH8
 
4.3.9 Synthesis of N7-(2,4-dinitrophenyl)-6-fluoro-N2-[5-(pyridin-3-yl)-1,3,4-
thiadiazol-2-yl]-1,3-benzothiazole-2,7-diamine: (SH9) 
Procedure: 
 0.0025 mole of 7-chloro-6-fluoro-N-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-
1,3-benzothiazol-2-amine was treated with equimolar quantity (0.0025 mole) of         
4 – nitro aniline was substituted and refluxed for 2 hours in the presence of DMF. The 
mixture was then cooled and poured in to crushed ice. The solid separated was 
filtered, dried and recrystallized from benzene and absolute alcohol (1:1).  
(Gupta Akhilesh et al., 2010) 
 
Reaction: 
N
S
NH
F
NH
S
NN
N
NO2
SH4
NH2
NO2
DMF,Reflux 2 hrsN
S
NH
F
Cl
S
NN
N
SH9
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4.3.10 Synthesis of 6-fluoro-7 N2-[5-(2-aminophenyl)-1, 3, 4-thiadiazol-2-yl] -N7-
(2-nitrophenyl)-1, 3-benzothiazole-2, 7-diamine:(SH10) 
Procedure: 
 0.0025 mole of 7-chloro-6-fluoro-N-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-
yl]-1-3-benzothiazol-2-amine was treated with equimolar quantity (0.0025 mole) of   
2 – nitro aniline was substituted and refluxed for 2 hours in the presence of DMF. The 
mixture was then cooled and poured in to crushed ice. The solid separated was 
filtered, dried and recrystallized from benzene and absolute alcohol (1:1).  
(Gupta Akhilesh et al., 2010) 
Reaction: 
N
S
NH
F
NH
S
NN
NH2
NO2SH5
N
S
NH
F
Cl
S
NN
NH2
NH2
NO2
DMF, Reflux 2 hrs
SH10
 
4.3.11 Synthesis of 6-fluoro-N2-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-yl] -N7-(4-
nitrophenyl)-1,3-benzothiazole-2,7-diamine: (SH11) 
Procedure: 
 0.0025 mole of 7-chloro-6-fluoro-N-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-
yl]-1-3-benzothiazol-2-amine was treated with equimolar quantity (0.0025 mole) of    
4 – nitro aniline was substituted and refluxed for 2 hours in the presence of DMF. The 
mixture was then cooled and poured in to crushed ice. The solid separated was 
filtered, dried and recrystallized from benzene and absolute alcohol (1:1).  
(Gupta Akhilesh et al., 2010) 
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Reaction:
N
S
NH
F
NH
S
NN
NH2
NO2
SH5
N
S
NH
F
Cl
S
NN
NH2
NH2
NO2
DMF,Reflux 2 hrs
SH11
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5. BIOLOGICAL EVALUATION 
5.1. Evaluation of Antimicrobial Activity:      
 The antimicrobial screening of the synthesized compounds (SH6-SH11) were 
carried out by determining the zone of inhibition using disc diffusion method. The 
synthesized compounds were dissolved in DMSO and sterilized by filtering through 
0.45 μm millipore filter. Final inoculums of 100 µl suspension containing 108 CFU/ 
ml of each bacterium and fungus used.  Nutrient agar (anti-bacterial activity) and 
sabouraud’s dextrose agar medium (anti-fungal activity) was prepared and sterilized 
by an autoclave (121° C and 15 lbs for 20 minutes) and transferred to previously 
sterilized petridishes (9 cm in diameter). After solidification, petriplates were 
inoculated with bacterial organisms in sterile nutrient agar medium at 45° C, and 
fungal organism in sterile sabouraud’s dextrose agar medium at 45° C in aseptic 
condition. Sterile Whatmann filter paper discs (previously sterilized in U.V. lamp) 
were impregnated with synthesized compounds at a concentration of 25 and 100 
µg/disc were placed in the organism-impregnated petri plates under sterile condition. 
The plates were left for 30 minutes to allow the diffusion of compounds at room 
temperature. Antibiotic discs of ciprofloxacin (100 µg/disc) and ketaconazole (100 
µg/disc) were used as positive control, while DMSO used as negative control. Then 
the plates were incubated for 24 hours at 37 ± 1° C for antibacterial activity and 48 
hours at 37 ± 1° C for anti-fungal activity. The zone of inhibition was calculated by 
measuring the minimum dimension of the zone of no microbial growth around the 
disc.  
5.2. Acute Oral Toxicity Studies:       
 The oral acute toxicity of synthesized compounds SH8 and SH11 was 
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determined by using albino mice of either sex (20 – 25 gms) maintained under 
standard husbandry conditions. This involves the estimation of median lethal dose 
(LD50), which is the dose that kills 50% of the animal population within 24 hours of 
the post treatment of the test substance. The acute oral toxic class method (OECD 
423) was adopted. The animals used for the studies where in accordance with 
principles of laboratory animal care and were approved by institutional animal ethical 
committee. The animals were fasted overnight prior to the experiment and were then 
grouped (3 mice per group). They were treated intra-peritoneally with different doses 
of the test compounds (5, 50, 300 mg/kg). The animals were then observed for 24 
hours for any behavioral effects such as nervousness, excitement, dullness, 
incoordination or even death. Acute toxic class (OECD guidelines No. 423) method of 
CPCSEA was adopted for toxicity studies. 1/5th of the lethal dose was taken as 
effective dose ED50 (Therapeutic dose).  
5.2. Evaluation of Anti-Inflammatory Activity: 
The anti-inflammatory activity of the synthesized derivative SH8 and SH11 was 
evaluated by carrageenan-induced paw oedema method. Wistar albino rats of either sex 
(150 – 200 g) were randomly selected and the animals were divided into control, standard 
and test groups, each consisting of three animals. The first group was treated with 1% 
polyethylene glycol suspension which served as control, second group was 
administered with a dose of 20 mg/kg suspension of diclofenac sodium intra-
peritoneally which served as standard and other groups were treated with 50 mg/kg of 
suspension of test compounds in 1% polyethylene glycol. After 30 minutes, the rats 
were injected with 0.1 ml of carrageenan (1% w/v) to the sub plantar region of left 
paw of the rats. The volume of paw was measured using mercury displacement 
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technique with the help of plethysmograph in control and animals treated with 
standard and test compounds at 0, 1, 2 and 3 hour after injection of carrageenan.  
The percentage inhibition of oedema was calculated by using formula,  
           Percentage Reduction = ௏೎ି௏೟
௏೎
	X	100 
Where, Vt = mean paw volume of the test drug,  
 Vc = mean paw volume of the control 
From the data obtained, the mean oedema volume and percentage reduction in 
oedema was calculated. 
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6. RESULTS AND DISCUSSION 
6.1. Synthetic Scheme 
F
Cl
NH2
Br2/NH3 CH3
CH3
N
S
NH2
SH1
DMF
3-chloro-4-fluoroaniline
RCOOH, POCl3
Step 2
Step 3
Step 4
Reflux 18-24 hrs
Ammonia,
NH2.NH2.H2O,
Carbon disulphide,
Sodium chloroacetate
C2H5OH
KSCN, CH3COOH
Reflux 2 hrs
N
S
NH
F
Cl
S
NH NH2
N
S
NH
F
Cl
S
NN
R
SH2
SH3 - SH5
NH2
SH6 - SH11
N
S
NH
F
R'
S
NN
R
0oC
Step 1
R'
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Different substitutions in the compounds SH6 – SH11 
 
1,3-benzothiazole and 1,3,4-thiadiazole are the most common and important 
groups among the nitrogen and sulphur containing heterocyclic compounds. Many 
methods had been reported in the literature for the synthesis of 1,3 benzothiazole such 
as condensation of o-aminothiophenol with aldehydes, cyclization of thioformanilides 
using different reagent, coupling between thiophenols and aromatic nitriles, synthesis 
using anilines and also by using microwave irradiation method. Among this synthesis 
of benzothiazole by using anilines is the most common method which involves the 
reaction of different substituted aniline with potassium thiocynate in the presence of 
glacial acetic acid.  
The substitutions of fluorine in the benzothiazole moiety increases lipid 
solubility which in turn increases the transport and absorption of drug in vivo and a 
S. No Compound Code R’ R 
1 SH6 
NH2
NO2
 
O  2 SH7 
NH2
NO2  
3 SH8 
NH2
NO2
 
N  4 SH9 
NH2
NO2  
5 SH10 
NH2
NO2
 
NH2
 6 SH11 
NH2
NO2  
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strong electron withdrawing inductive effect of fluorine can significantly influence 
reactivity and stability of functional groups and the reactivity of neighboring reaction 
centers. (Kuntal Hazra et al., 2011) Hence to fluorinate the benzothiazole 4-fluoro 3-
chloro aniline was chosen. 
         1,3,4-thiadiazole can be synthesized from thiosemicarbazides, dimethyl 
formamaide and hydrazine. The most common method to synthesize 5-substituted 2-
amino-1,3,4-thiadiazoles is form thiosemicarbazides which involves acyclation of 
thiosemicarbazide followed by dehydrative cyclization using any of the below 
mentioned agents sulfuric acid, polyphosphoric acid, phosphorus oxychloride, 
phosphorus halides or more recently methane sulfonic acid.    
 In this present study, a series of fluorobenzothiazole incorporated 1,3,4-
thiadiazole compounds were synthesized by the following strategy: initially 3-chloro 
4-fluoro-aniline reacted with potassium thiocynate in the presence of glacial acetic 
acid and bromine at 0° C to give the corresponding 2-amino-6-fluoro-7-chloro-(1,3)-
benzothiazole, which further reacts with hydrazine hydrade, ammonia, carbon 
disulphide, sodium chloroacetate in the presence of ethanol to form 2-
thiosemicarbazide substituted 6-fluoro-7-chloro-(1,3)-benzothiazole. The third step 
involves acyclation of 2-thiosemicarbazide followed by dehydrative cyclization using 
phosphorous oxy chloride to form 1,3,4 thiadiazole moiety, in this step different 
aromatic acids were also substituted. Then the 1,3,4 thiadiazole substituted compound 
was treated with ortho and para nitro anilines, in the presence of DMF to obtain 
different fluorobenzothiazole incorporated 1,3,4 thiadiazole compounds. 
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6.2. Interpretation of spectral data of synthesized compounds (SH1 – SH11) 
6.2.1. 2-amino-6-fluoro-7-chloro-(1,3)-benzothiazole (SH1) 
UV: (Fig-56) 
λmax (MeOH)                              240.0 (ε max 1.0140) 
IR (Kbr): (Fig-57) 
 
 
 
 
 
 
 
 
 
 
NMR (DMSO – d6): (Fig-58) 
 
 
 
 
(2 aromatic protons, 2 protons on Nitrogen) 
 
 
 
 
 
S. No Wave Number (cm-1) Assignment 
1 3288 N – H stretching 
2 3083 Aromatic C – H stretching 
3 1637 C = N stretching 
4 1543 Aromatic C = C ring stretching 
5 1346 Aromatic C = N stretching 
6 1193 C – F stretching 
7 683 C – Cl stretching 
8 617 C – S stretching 
S. No δ Assignment 
1 8.09 1H, d, Ar – H of benzothiazole 
2 7.20 1H, d, Ar – H  of benzothiazole 
3 4.0 2H, s, NH 
N
S
NH2
Cl
F
7.20
8.09
4.0
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Fig.56: UV Spectrum of compound SH1 
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Fig.57:  IR Spectrum of compound SH1 
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Fig-58: 1H NMR Spectra of the compound SH1
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6.2.2. N-(7-chloro-6-fluoro-1,3-benzothiazol-2-yl)hydrazine carbothioamide 
(SH2) 
UV: (Fig-59) 
λmax (MeOH)                              265.5 (ε max 1.6844) 
IR (KBr): (Fig-60) 
S. No Wave Number (cm-1) Assignment 
1 3473 N – H stretching 
2 3077 Aromatic C – H stretching 
3 1645 C = N stretching 
4 1452 Aromatic C = C ring stretching 
5 1337 Aromatic C – N secondary vibrations 
6 1216 Aliphatic C – N vibrations 
7 1194 C – F stretching 
8 1071 Aliphatic C = S stretching 
9 715 C – Cl stretching 
10 686 C – S stretching 
NMR (DMSO – d6): (Fig-61) 
N
S
NH
F
Cl
NH NH2
S
7.20
8.09
4.0 2.0
2.0
 
(2 aromatic protons, 4 protons on nitrogen) 
 
 
 
 
 
 
 
 
S. No δ Assignment 
1 8.09 1H, d, Ar – H of benzothiazole 
2 7.20 1H, d, Ar – H  of benzothiazole 
3 4.0 1H, s, NH 
4 2.0 3H, s, NH 
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Fig.59: UV Spectrum of compound SH2 
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Fig.60:  IR Spectrum of compound SH2 
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Fig-61: 1H NMR Spectra of the compound SH2
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6.2.3. 7-chloro-6-fluoro-N-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-1,3-benzothiazol-
2-amine (SH3) 
UV: (Fig-62) 
λmax (MeOH)                              282.0 (ε max 2.6021) 
 
IR (KBr): (Fig-63) 
S. No Wave Number (cm-1) Assignment 
1 3392 N – H stretching 
2 3032 Aromatic C – H stretching 
3 1653 C = N stretching 
4 1477 Aromatic C = C ring stretching 
5 1337 Aromatic C – N secondary vibrations 
6 1289 C – O bending 
7 1029 C – F stretching 
8 844 C – Cl stretching 
9 714 Aromatic C – H bending 
10 642 C – S stretching 
 
NMR (DMSO – d6) (Fig-64) 
 
 
 
(2 aromatic protons, 3 protons of furan, 1 proton on nitrogen) 
 
 
 
 
 
 
 
S. No δ Assignment 
1 8.09 1H, d, Ar – H of benzothiazole 
2 7.20 1H, d, Ar – H  of benzothiazole 
3 7.4 1H, d, CH of furan 
4 6.3 2H, d, CH of furan 
5 4.0 1H, s, NH 
N
S
NH
F
Cl
S
NN
O
8.09
7.20
4.0
6.3
7.4
6.3
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MASS: (Fig-65) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
N
S
NH
F
Cl
N N
S O
N
SF
Cl
+
m/z - 185
F
Cl
+
m/z - 126
-CHNS
.
-CH
.
.
.
F
Cl
+
m/z - 116
N
S
Cl
F
NH
.
m/z - 200
N
SF
NH.
+
m/z - 165
N
S
NH.
+
m/z - 146
N
S
NH
F
Cl
N N
S
+
m/z - 284
N
S
NH
N N
S
Cl
+
m/z - 266
N
S
NH
N N
S
+
m/z - 233
-Cl
.
-F
.
-F
.
-Cl
.
m/z - 351
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Fig.62: UV Spectrum of compound SH3 
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Fig.63:  IR Spectrum of compound SH3 
69 
 
 
 
 
Fig-64: 1H NMR Spectra of the compound SH3 
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Fig-65: Mass Spectrum of the compound SH3 
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6.2.4. 7-chloro-6-fluoro-N-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazol-2-amine (SH4) 
UV: (Fig-66) 
λmax (MeOH)                              284.5 (ε max 0.8198) 
IR (KBr): (Fig-67) 
 
S. No Wave Number (cm-1) Assignment 
1 3292 N – H stretching 
2 3090 Aromatic C – H stretching 
3 3022 Aromatic Pyridine C – H stretching 
4 1632 C = N stretching 
5 1543 C = C, C = N ring stretching in pyridine 
6 1454 Aromatic C = C ring stretching 
7 1341 Aromatic C – N secondary vibrations 
8 1032 C – F stretching 
9 844 C – Cl stretching 
10 716 Aromatic C –H bending 
11 645 C – S stretching 
 
 
NMR (DMSO – d6): (Fig-68) 
 
N
S
NH
F
Cl
S
NN
N
8.09
7.20
4.0
8.55
7.44
8.81
7.97
 
 
 
(6 aromatic protons, 1 proton on nitrogen) 
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MASS: (Fig-69) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
N
S
Cl
F
NH
.
m/z - 200
N
S
NH
F
Cl
N N
S N
N
S
NH
F
N N
S N
.
NH
N N
S N
+
m/z - 329
-F
.
N
S
NH
N N
S N+
m/z - 312 m/z - 161
-NH
.
m/z - 176
m/z - 78
N N
S N
N
+
+
-C2HN2S
.
m/z - 362
 
 
 
S. No δ Assignment 
1 8.85 1H, d, CH of pyridine 
2 8.81 1H, s, CH of pyridine 
3 8.09 1H, d, Ar – H of benzothiazole 
4 7.97 1H, d, CH  of pyridine 
5 7.44 1H, t, CH of pyridine 
6 7.20 1H, d, Ar – H  of benzothiazole 
7 4.0 1H, s, NH 
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Fig.66:UV Spectrum of Compound SH4
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Fig.67:  IR Spectrum of compound SH4 
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Fig-68: 1H NMR Spectra of the compound SH4 
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Fig-69: Mass Spectrum of the compound SH4
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6.2.5. N-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-yl]-7-chloro-6-fluoro-1,3-
benzothiazol-2-amine (SH5) 
UV: (Fig-70) 
λmax (MeOH)                              280.5 (ε max 0.4451) 
IR (KBr): (Fig-71) 
S. No Wave Number (cm-1) Assignment 
1 3388 N –H stretching 
2 3078 Aromatic C – H stretching 
3 1634 C = N stretching 
4 1546 N – H bending 
5 1458 Aromatic C = C ring stretching 
6 1116 C – F stretching 
7 809 C – Cl stretching 
8 685 C – S stretching 
 
NMR (DMSO – d6): (Fig-72) 
 
N
S
NH
F
Cl
S
NN
H2N
8.09
7.20
4.0
6.52
6.97
7.23 6.68
4.0
 
 
 
(6 aromatic protons, 3 protons on nitrogen) 
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MASS: (Fig-73) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No δ Assignment 
1 8.09 1H, d, Ar – H of benzothiazole 
2 7.23 1H, d, CH of benzene 
3 6.97 1H, t,  CH of benzene 
4 6.68 1H, t,  CH of benzene 
5 6.52 1H, d, Ar – H  of benzene 
6 7.20 1H, d, Ar – H  of benzothiazole 
7 4.0 3H, s, NH 
N
SF
Cl
+
m/z - 185
F
Cl
+
m/z - 126
-CHNS
.
-CH
.
.
.
F
Cl
+
m/z - 116
N
S
Cl
F
NH
.
m/z - 200
N
S
NH
F
N N
S
Cl
+
m/z - 284
m/z - 249
m/z - 232
-F
.
m/z - 376
N
S
NH
F
Cl
N N
S
NH2
N
S
NH
F
N N
S
+
-Cl
.
N
S
NH
N N
S+
m/z - 358
N
S
NH
Cl
N N
S
NH2
+
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Fig.70:UV Spectrum of Compound SH5 
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Fig.71:  IR Spectrum of compound SH5 
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Fig-72: 1H NMR Spectra of the compound SH5 
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Fig-73: Mass Spectrum of the compound SH5
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6.2.6. 6-fluoro-N2-[5-(furan-2-yl)-1, 3, 4-thiadiazol-2-yl]-N7-(2-nitrophenyl)-1,3-
benzothiazole-2, 7-diamine (SH6) 
UV: (Fig-74) 
λmax (MeOH)                              293.5 (ε max 0.2321) 
IR (KBr): (Fig-75) 
S. No Wave Number (cm-1) Assignment 
1 3477.49 N – H asymmetrical stretching 
2 2925.18 Aromatic C – H stretching 
3 1731.91 C – H out of plane bending 
4 1569.79 C = N stretching 
5 1507.47 NO2  asymmetrical stretching 
6 1345.48 C – N stretching 
7 1169.53 N – N stretching 
8 1101.20 C – O stretching 
9 1016.47 2 – substituted furans 
10 779.06  C – S stretching 
11 742.44 C – H out of plane bending 
 
NMR (DMSO – d6): (Fig-76-78) 
N
S
NH
F
NH
S
NN
O
NO2
7.54
7.31 4.39
6.86 6.68
7.87
4.39
8.20
7.60
7.17
7.68
 
(6 aromatic protons, 3 proton of furan, 2 protons on nitrogen) 
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MASS: (Fig-79) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
N
S
NH
F
NH
S
NN
O
NO2
N
SF
NH
S
N N
O
N
SF
NH
S
N N
O
N
SF
NH
S
N N
N
SF
NH
NO2
HN
S
NN
O
+
m/z=454
m/z=270
m/z=166
m/z=394
m/z=301
m/z=365
m/z=390
N
S
NH
F
NH
S
NN
C=CH
NO2
-C2H2O
α - cleavage 
-NO2
CH CH
-Furoic acid
 
S. No δ Assignment 
1 8.20 1H, d, Ar – H  
2 7.87 1H, d, CH of furan 
3 7.68 1H, t, Ar – H  
4 7.60 1H, t, Ar – H  
5 7.54 1H, d, Ar – H of benzothiazole 
6 7.31 1H, d, Ar – H  of benzothiazole 
7 7.17 1H, d, Ar – H  
8 6.86 1H, d, CH of furan 
9 6.68 1H, t, CH of furan 
10 4.39 2H, s, NH 
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Fig.74:UV Spectrum of Compound SH6 
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Fig.75:  IR Spectrum of compound SH6 
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Fig-76: 1H NMR Spectra of the compound SH6 
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Fig-77: 1H NMR Spectra of the compound SH6 (Zoom View 1) 
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Fig-78: 1H NMR Spectra of the compound SH6 (Zoom View 2)
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Fig.79: Mass Spectrum of the compound SH6 
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6.2.7. N7-(2,4-dinitrophenyl)-6-fluoro-N2-[5-(furan-2-yl)-1,3,4-thiadiazol-2-yl]-
1,3-benzothiazole-2,7-diamine(SH7) 
UV: (Fig-80) 
λmax (MeOH)                              287.5 (ε max 0.4285) 
IR (KBr): (Fig-81) 
 
  
 
 
 
 
 
 
 
 
 
NMR (DMSO – d6): (Fig-82-84) 
N
S
NH
F
NH
S
NN
O
NO2
7.52
7.30 4.39
6.86 6.68
7.87
4.39
7.26
8.03
7.26
8.03
 
(8 aromatic protons, 3 proton of furan) 
S. No Wave Number (cm-1) Assignment 
1 3361.71 N – H asymmetrical stretching  
2 2923.85 Aromatic C – H stretching 
3 1923.56 Aromatic C – H out of plane bending 
4 1505.47 C = N stretching 
5 1301.98 C – H stretching 
6 1281.62 C – N stretching 
7 1013.55 2 – substituted furans 
8 753.74  C – S stretching 
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MASS: (Fig-85) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
   
 
 
 
 
 
 
 
S. No δ Assignment 
1 8.03 2H, d, Ar – H –  of aniline group 
2 7.87 1H, d, CH of furan 
3 7.52 1H, d, Ar – H of benzothiazole 
4   7.26-7.30 3H, m, Ar – H   
5 6.86 1H, d, CH of furan 
6 6.68 1H, t, CH of furan 
7 4.39 2H, s, NH 
N
S
NH
F
NH
S
NN
O
NO2
N
SF
NH
NO2
HN
S
NN
O+a-cleavage
CH CH
N
S
NH
F
NH
S
NN
O
NO2
N
S
NH
S
NN
O
F
+
NH
NO2
N
S
NH
F
NH
S
NN
O
N
S
NH
NH
S
NN
O
m/z=454
m/z=288
m/z=332
m/z=313
m/z=391
m/z=428
-F
a-cleavage
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Fig.80:UV Spectrum of Compound SH7 
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Fig.81:  IR Spectrum of compound SH7 
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Fig-82: 1H NMR Spectra of the compound SH7 
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Fig-83: 1H NMR Spectra of the compound SH7 (Zoom View 1)
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Fig-84: 1H NMR Spectra of the compound SH7 (Zoom View 2)
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Fig.85: Mass Spectrum of the compound SH7
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6.2.8. 6-fluoro-N7-(2-nitrophenyl)-N2-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazole-2,7-diamine(SH8) 
UV: (Fig-86) 
λmax (MeOH)                              289.5 (ε max 1.0659) 
IR (KBr): (Fig-87) 
 
 
 
 
 
  
  
 
NMR(DMSO – d6): (Fig-88-90) 
N
S
NH
F
NH
NO2
S
NN
N
7.32
7.55
6.33
6.33
8.04 7.47
7.16
7.68
7.60
8.20
9.09
8.70
 
(10 aromatic protons, 2 protons on Nitrogen) 
S. No Wave Number (cm-1) Assignment 
1 3348.87 N – H asymmetrical stretching  
2 2851.37 Aromatic C – H stretching 
3 1628.84 Aromatic C – H out of plane bending 
4 1507.01 C = N stretching 
5 1301.98 C – H stretching 
6 1283.77 C – N stretching 
7 1101.29 C – F stretching 
8 977.00  N – N stretching 
9 881.74  C – H out of plane bending 
10 742.33 C – S stretching 
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MASS: (Fig-91) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
S. No δ Assignment 
1 9.09 1H, s, CH of pyridine 
2 8.70 1H, d, CH of pyridine 
3 8.20 1H, d, Ar – H   
4    8.04  1H, d, CH of pyridine 
5 7.68 1H, t, Ar – H  of aniline group 
6 7.60 1H, t, Ar – H  of aniline group 
7 7.55 1H, d, Ar – H of benzothiazole 
8 7.47 1H, t, CH of pyridine 
9 7.32 1H, d, Ar – H  of benzothiazole 
10 7.16 1H, d, Ar – H   
11 6.33 2H, s, NH 
N
S
NH
F
NH
NO2
S
NN
N
m/z 303
m/z 162
N
S
NH
F
NH
NO2
S
NN
N+
m/z 343
N
S
NH
F
NH
S
NN
N
NO2
m/z 122
+
m/z 324
N
S
NH
NH
S
NN
N
-F
m/z 465
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      Fig.86:UV Spectrum of Compound SH8 
102 
 
 
Fig.87:  IR Spectrum of compound SH8 
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Fig-88: 1H NMR Spectra of the compound SH8 
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Fig-89: 1H NMR Spectra of the compound SH8 (Zoom View 1) 
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Fig-90: 1H NMR Spectra of the compound SH8 (Zoom View 2) 
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Fig.91: Mass Spectrum of the compound SH8
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6.2.9. 6-fluoro-N7-(4-nitrophenyl)-N2-[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,3-
benzothiazole-2,7-diamine(SH9) 
UV: (Fig-92) 
λmax (MeOH)                              306.5 (ε max 0.4948) 
IR (KBr): (Fig-93) 
 
 
 
 
 
 
 
 
 
 
 
 
NMR (DMSO – d6): (Fig.94-96) 
N
S
NH
F
NH
S
NN
N
NO2
8.04
7.34 7.34
8.04
7.23
7.38
6.62
6.62
8.05 7.47
9.09
8.70
 
(10 aromatic protons, 2 protons on Nitrogen) 
S. No Wave Number (cm-1) Assignment 
1 3345.55 N – H asymmetrical stretching  
2 2857.14 Aromatic C – H stretching 
3 1622.15 Aromatic C – H out of plane bending 
4 1515.16 C = N stretching 
5 1330.14 C – H stretching 
6 1273.17 C – N stretching 
7 1108.27 C – F stretching 
8 970.03  N – N stretching 
9 881.93  C – H out of plane bending 
10 742.33 C – S stretching 
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MASS: (Fig-97) 
The structure of the compound was further confirmed by mass spectroscopy and the 
molecular ion peak was found to be 463.31 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No δ Assignment 
1 9.09 1H, s, Ar – CH  
2 8.70 1H, d, Ar – CH   
3 8.05-8.04 3H, m, Ar – H   
4 7.47 1H, t, Ar – CH   
5 7.38 1H, d, Ar – H of benzothiazole 
6 7.34 2H, d, Ar – H  
7 7.23 1H, d, Ar – CH  of benzothiazole 
8 6.62 1H, s, NH 
N
S
N H
N H
NO 2
F
S
N N
N
N
S
N H
+
N H
NO 2
F
S
N N
N
N
S
N H
+
N H
NO 2
F
S
N N
N
m /z 465
N
S
N H
N H
NO 2
F
S
N N
N
C
+
CH CH
m /z 438
N
S
N H
N H
NO 2
F
S
N
C
+
N
m /z 387
C
+
N
S
N H
F
S
N N
N
N H
NO 2
a-cleavage
N
C
+
S
N H
NO 2
F
NH
S
N N
N+
m /z 303
a-cleavage
e
-
m /z 465
m /z 465
m /z 328
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Fig.92:UV Spectrum of Compound SH9
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Fig.93:  IR Spectrum of compound SH9 
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Fig-94:1H NMR Spectra of the compound SH9 
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Fig-95: 1H NMR Spectra of the compound SH9(Zoom View 1) 
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Fig-96: 1H-NMR Spectra of the compound SH9 (Zoom View 2) 
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Fig.97: Mass Spectrum of the compound SH9
115 
 
6.2.10. N2-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N7-(4-nitrophenyl)-
1,3-benzothiazole-2,7-diamine (SH10) 
UV: (Fig.98) 
λmax (MeOH)     288.0 (ε max  0.4660) 
IR (KBr): (Fig.99) 
 
 
 
 
 
 
 
 
 
 
 
 
NMR (DMSO – d6): (Fig-100-102) 
N
S
NH
F
NH
S
NN
NH2
NO2
7.29
7.12
8.20
7.60
7.46
4.47
4.47
7.43 6.96
7.23
6.77
7.68
6.35
 
(10 aromatic protons, 4 protons on Nitrogen) 
 
S. No Wave Number (cm-1) Assignment 
1 3351.36 N – H asymmetrical stretching  
2 2925.41 Aromatic C – H stretching 
3 1627.88 Aromatic C – H  out of plane bending 
4 1506.57 C = N stretching 
5 1346.02 C – N stretching 
6 1101.57 C – F stretching 
7 1016.33 N – N stretching 
8 694.78  C – H out of plane bending 
9 743.99  C – S stretching 
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MASS: (Fig-103) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
S. No δ Assignment 
1 8.20 1H, d,  of aniline group 
2 7.68 1H, t, Ar – H  of aniline group 
3 7.60 1H, t, Ar – H  of aniline group 
4 7.46 1H, d, Ar – H  of aniline group 
5 7.43 1H, d,  Ar – H   
6 7.29 1H, d, Ar – H  of benzothiazole 
7 7.23 1H, t,   Ar – H   
8 7.12 1H, d, Ar – H  of Benzothiazole 
9 6.96 1H, t,   Ar – H   
10 6.77 1H, d,   Ar – H   
11 6.35 2H, s, NH2 
12 4.47 2H, s, NH 
N
S
N H
F
N H
S
NN
NH 2
NO 2
N
S
N H
F
N H
S
NN
C +
NO 2
-NH 2
C
+
N
S
N H
F
S
NN
NH 2
C
+
N
H
S
NH
F
N
S
N H
F
N H
S
C
+
NN
NO 2
N
S
N H
F
N H
S
C
+
NN
N
S
N H
N H
S
C
+
NN
NO 2
-NO 2-F
NH
NO 2
+
m /z  4 7 9 m /z  4 6 3
m /z  3 8 7
m /z  34 2m /z  3 68
m /z  1 6 8
m /z  3 4 2
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Fig.98:UV Spectrum of Compound SH10
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Fig.99:  IR Spectrum of compound SH10 
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Fig-100: 1H NMR Spectra of the compound SH10 
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Fig-101: 1H NMR Spectra of the compound SH10 (Zoom View 1) 
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Fig-102: 1H NMR Spectra of the compound SH10 (Zoom View 2) 
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Fig.103: Mass Spectrum of the compound SH10
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6.2.11. N2-[5-(2-aminophenyl)-1,3,4-thiadiazol-2-yl]-6-fluoro-N7-(2-nitrophenyl)-
1,3-benzothiazole-2,7-diamine (SH11) 
UV: (Fig-104) 
λmax (MeOH)                              290.0 (ε max 0.9673) 
IR (KBr): (Fig-105) 
 
 
 
 
 
 
 
 
 
 
 
 
NMR(DMSO – d6): (Fig-106-108) 
N
S
NH
F
NH
S
NN
NH2
O2N
7.51
7.29
4.44
4.44
7.27
8.03
7.27
8.03
7.41 6.96
7.23
6.74
4.45
 
(10 aromatic protons, 4 protons on Nitrogen) 
 
S. No Wave Number (cm-1) Assignment 
1 3482.56 N – H asymmetrical stretching  
2 2919.88 Aromatic C – H stretching 
3 1629.00 Aromatic C – H  out of plane bending 
4 1504.86 C = N stretching 
5 1285.90 C – N stretching 
6 1109.11 C – F stretching 
7 1015.26 N – N stretching 
8 842.98  C – H out of plane bending 
9 751.72  C – S stretching 
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MASS: (Fig-109) 
The structure of the compound was further confirmed by its fragmentation peaks 
which are as follows: 
 
 
 
 
 
 
 
 
 
 
 
S. No δ Assignment 
1 8.03 2H, d, Ar – H of aniline group 
2 7.51 1H, d, Ar – H of benzothiazole 
3 7.41 1H, d, Ar – H  
4 7.23-7.29 4H, m, Ar – H   
7 6.96 1H, t, Ar – H   
8 6.74 1H, d, Ar – H   
9 4.45 2H, s, NH2 
10 4.44 2H, s, NH 
m/z 479
N H
NO 2
N
S
NH
N H
NO 2
F
S
N N
NH2
N
S
N H
+
NH
NO 2
F
S
N N
NH 2
C
+
N
S
NH
F
S
N N
NH 2
+
m/z 342
-F
+
C
+
N
S
N H
N H
NO 2
S
N N
NH 2
m/z 460
CH C H
C
+
N
S
N H
NH
NO 2
S
N N
NH 2
m/z 434
e
-
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Fig.104:UV Spectrum of Compound SH11 
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Fig.105:  IR Spectrum of compound SH11 
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Fig-106: 1H NMR Spectra of the compound SH11 
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Fig-107: 1H NMR Spectra of the compound SH11 (Zoom View 1) 
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Fig-108: 1H NMR Spectra of the compound SH11 (Zoom View 2) 
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Fig.109: Mass Spectrum of the compound SH11 
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6.3. Physical and Analytical Data of the Synthesized Compounds 
Code Name Nature Solubility 
Molecular 
Weight (gm) 
Molecular 
Formula 
Melting 
Point (°C) 
Percentage 
Yield (%) 
Rf Value 
SH1 
7-chloro-6-fluoro-
1,3-benzothiazol-2-
amine 
 
Light 
yellow 
colour 
powder 
Freely soluble: 
Methanol, ethyl acetate, 
ethanol and acetone 
Sparingly soluble: 
water, benzene and 
chloroform 
202.63 C7H4ClFN2S 212 47.5 
 
0.57 
 
SH2 
N-(7-chloro-6-
fluoro-1,3-
benzothiazol-2-
yl)hydrazinecarboth
ioamide 
 
Light 
brownish 
white 
colour 
Freely soluble: DMF 
Methanol, ethanol, ethyl 
acetate, benzene, 
chloroform and acetone 
Sparingly soluble: water 
276.74 C8H6ClFN4S2 241 51.63 0.69 
SH3 
 
7-chloro-6-fluoro-
N-[5-(2-furyl)-
1,3,4-thiadiazol-2-
yl]-1,3-
benzothiazol-2-
amine 
 
Brown 
colour 
solid 
Freely soluble:  DMF 
Methanol, ethyl acetate, 
ethanol and acetone 
Sparingly soluble: 
chloroform and  water 
352.79 C13H6ClFN4OS2 224 36.75 
 
 
 
0.62 
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SH4 
 
7-chloro-6-fluoro-
N-[5-(pyridin-3-yl)-
1,3,4-thiadiazol-2-
yl]-1,3-
benzothiazol-2-
amine 
 
Pale pink 
colour 
solid 
 
Freely soluble:  DMF 
Methanol, ethyl acetate, 
benzene, chloroform and 
acetone 
Soluble: ethanol 
Sparingly soluble: 
hexane and water 
362.21 C14H7ClFN5S2 192 42.19 0.57 
SH5 
 
7-chloro-6-fluoro-
N-[5-(2-
aminophenyl)-
1,3,4-thiadiazol-2-
yl]-1,3-
benzothiazol-2-
amine 
 
 
Dirty white 
colour 
powder 
 
Freely Soluble:  DMF 
Methanol and acetone 
Sparingly soluble: 
ethanol, ethyl acetate, 
hexane and water 
Very slightly soluble: 
benzene and chloroform 
377.84 C15H9ClFN5S2 227 39.42 0.53 
SH6 
6-fluoro-N2-[5-
(furan-2-yl)-1,3,4-
thiadiazol-2-yl]-N7-
(2-nitrophenyl)-1,3-
benzothiazole-2,7-
diamine 
Yellow 
colour 
powder 
Soluble:  Methanol  
DMF and DMSO   
Sparingly soluble:   
acetone, ethyl acetate, 
chloroform and  ethanol 
454.45 C19H11FN6O3S2 210 54.79 
 
 
 
0.81 
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SH7 
N7-(2,4-
dinitrophenyl)-6-
fluoro-N2-[5-(furan-
2-yl)-1,3,4-
thiadiazol-2-yl]-
1,3-benzothiazole-
2,7-diamine 
Orange 
colour 
powder 
Freely soluble: 
Methanol,  DMF  and 
DMSO   
Sparingly soluble: ethyl 
acetate, acetone and 
ethanol 
Slightly soluble: 
benzene and chloroform 
 
454.45 
 
C19H11FN6O3S2 
 
212 
 
43.53 
 
 
0.69 
 
SH8 
6-fluoro-N7-(2-
nitrophenyl)-N2-[5-
(pyridin-3-yl)-
1,3,4-thiadiazol-2-
yl]-1,3-
benzothiazole-2,7-
diamine 
Green  
colour 
powder 
 
Freely soluble: 
Methanol,  DMF and 
DMSO 
Sparingly soluble: 
ethanol and chloroform 
Slightly soluble: ethyl 
acetate and acetone 
 
465.48 C20H12FN7O2S2 216 54.59 0.84 
SH9 
6-fluoro-N2-[5-
(furan-2-yl)-1,3,4-
thiadiazol-2-yl]N7-
(2-nitrophenyl)-1,3-
benzothiazole-2,7-
diamine 
Dark green 
colour 
powder 
 
Soluble: Methanol,  
DMF and DMSO 
Sparingly soluble: 
ethanol, acetone and  
chloroform 
 
465.48 C20H12FN7O2S2 217 47.09 0.81 
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SH10 
6-fluoro-7 N2-[5-(2-
aminophenyl)-1, 3, 
4-thiadiazol-2-yl] -
N7-(2-nitrophenyl)-
1, 3-benzothiazole-
2, 7-diamine 
Yellow 
colour 
powder 
Freely soluble:  DMF, 
Methanol and DMSO4 
Slightly soluble:  
ethanol ethyl acetate and 
water. 
479.51 C21H14FN7O2S2 220 49.54 
 
0.58 
 
SH11 
6-fluoro-N2-[5-(2-
aminophenyl)-
1,3,4-thiadiazol-2-
yl] -N7-(4-
nitrophenyl)-1,3-
benzothiazole-2,7-
diamine 
Orange 
colour 
powder 
Freely soluble: DMF, 
methanol  and DMSO4 
Slightly soluble: 
chloroform, benzene 
Very slightly soluble: 
ethanol, acetone, water 
479.51 C21H14FN7O2S2 217 44.04 0.78 
135 
 
6.4.a. Screening of Antibacterial Activity 
 The synthesized compounds were evaluated for in vitro antibacterial activity 
against gram negative bacteria Proteus vulgaris NCTC 4635 and gram positive 
bacteria Micrococcus leutus NL98. These are the agents commonly causes urinary 
tract infection, nosocomial infection, biliary tract infection. The gram negative 
organism Proteus vulgaris causes urinary tract infections and wound infections. The 
gram positive organism Micrococcus leutus causes endocarditis, septic arthritis, 
meningitis and caveating pneumonia. As per the data obtained, it was confirmed that 
all the tested compounds possessed antibacterial activity against both gram positive 
and gram negative organisms. The SH6, SH7, SH11 showed greater activity against 
Micrococcus leutus than Proteus vulgaris. Whereas SH8, SH9, SH10 showed greater 
activity against Proteus vulgaris than Micrococcus leutus However the antibacterial 
activity of all the synthesized compounds against the tested organism was found to be 
less than that of ciprofloxacin, a standard antibacterial drug at tested dose level. The 
results were tabulated in Table-1. 
6.4. b. Screening of Antifungal Activity 
The synthesized compounds were evaluated in vitro antifungal activity against 
fungal organism Aspergillus flavus ATCC 46646. The organism causes serious lungs 
infection and bronchitis. As per the data obtained, it was confirmed that all the tested 
compounds possessed antifungal activity. However, SH11 exhibited potent anti-fungal 
activity against fungal organism among the tested compounds. However the anti-
bacterial activity of the SH11 against the tested organism was found to be less than 
that of antifungal standard drug ketoconazole at tested dose level. The results were 
tabulated in Table-1. 
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6.4. c. Acute Oral Toxicity 
The acute toxicity of the synthesized compounds SH8 & SH11 was determined 
by using albino swiss mice (20-25 gm). The animals were fasted for 24 h prior to the 
experiment and acute class toxic (OECD 423) method of CPCSEA was adapted for 
acute toxicity studies. The animals were treated up to the dose level of 300 mg and 
since no morbidity was observed up to that level, 1/6th of the lethal dose (50 mg/ kg 
b.w) was taken as effective dose ED50 (Therapeutic dose). 
6.4. d. Anti-Inflammatory Activity 
The synthesized derivatives, SH8 & SH11 were selected for the screening of 
anti-inflammatory activity using carrageenan induced paw edema method. The test 
compounds exhibited significant activity in acute inflammatory models in rats after            
1 h, 2 h and 3 h. The results were tabulated in Table-2. 
 The SH8 showed significant activity at 1 h, 2 h and 3 h and the mean paw 
oedema volume at these hours were 0.59±0.058, 0.69±0.057 and 0.80±0.066 
respectively. The compound was found to have statistically significant activity 
at 1st h, 2nd h but it was highly significant in 3rd h.  
 The SH11 showed significant activity at 1 h, 2 h and 3 h and the mean paw 
edema volume at these hours were 0.53±0.066, 0.61±0.066 and 0.72±0.066 
respectively. The compound was found to have statistically significant activity 
at 1st h, 2nd h but it was highly significant in 3rd h.  
 The standard drug diclofenac sodium was significant at 1 h, 2 h and 3 h and 
the activity at these hours were 0.46±0.066, 0.53±0.088 and 0.53±0.088 
respectively. The compound showed significant activity at 1h and 2 h but it 
was highly significant at 3 h. 
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The compounds SH8 & SH11 exhibited maximum inhibition of 45.51 % and 51.20 % 
respectively where as the standard diclofenac sodium showed reduction in oedema 
volume by 62.14 %.   
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Table 1: In vitro Antimicrobial Activity of Synthesized Compounds by Disc Diffusion Method 
 
 
Microorganisms  
 
Diameter of  Zone of Inhibition in mm 
 
 
 
 
 
SH6 SH7 SH8 SH9 SH10 SH11 
Ketaconazole 
(μg/disc) 
Ciprofloxacin 
(μg/disc) 
25 
(µg) 
100 
(µg) 
25 
(µg) 
100 
(µg) 
25 
(µg) 
100 
(µg) 
25 
(µg) 
100 
(µg) 
25 
(µg) 
100 
(µg) 
25 
(µg) 
100 
(µg) 100 100 
Micrococcus 
luteus 17 28 17 27 14 18 14 17 11 14 15 17.6 ----- 
32 
 
Proteus 
 vulgaris 14 17 12 16 22 26 17.6 19 12 14.6 12 16.1 ----- 
29 
 
Aspergillus 
flavus 11 16 14 18.6 17 21.6 21 23 21 25 23 27 30 ----- 
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Fig-82: Antibacterial Activity of Compound SH6 and SH8 against Tested Organisms 
 
 
 
 
 
Fig-82: Antifungal Activity of Compound SH11 against Tested Organism 
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Table 2:  Anti-Inflammatory Activity of Synthesized Compounds by Carrageenan Induced Paw Oedema Method 
 
S. No. Compound Code Dose (mg/kg) 
Paw Edema Volume (in ml) at 
0 hour 1 hour 2 hour 3 hour 
mean±SEM mean±SEM mean±SEM mean±SEM 
 
1 
 
Control  - 0.33±0.066 0.9±0.088 1.1±0.088 1.47±0.057 
2 Diclofenac Sodium 20 0.23±0.033 
0.46±0.066** 
(48.88) 
0.53±0.088** 
(51.51) 
0.53±0.088*** 
(62.14) 
3 SH8 50 0.53±0.057 
0.59±0.058* 
(34.44) 
0.69±0.057* 
(37.27) 
0.80±0.065*** 
(45.51) 
4 SH11 50 0.46±0.066 
0.53±0.066* 
(41.11) 
0.61±0.066** 
(44.54) 
0.72±0.066*** 
(51.20) 
 
n = 3 in each group.*p< 0.05, **p < 0.01 and ***p<0.001 when compared to control (One-way ANOVA followed by Bonferroni test)                     
Figures in the parenthesis indicate % inhibition of paw oedema
 
 
SUMMARY & CONCLUSION 
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7. SUMMARY AND CONCLUSION 
In recent year attention has increasingly been given to the synthesis 
compounds with combination of two heterocyclic nucleuses. In order to expand this 
we synthesized compounds which contains benzothiazole and 1,3,4 thiadiazole 
nucleuses. Individually benzothiazole and 1,3,4 thiadiazole nucleuses possess 
numerous biological activities as documented in literature. Hence this versatile 
biological significance inspired us to synthesize the compounds which contain 
combination of these two moieties in hope of getting molecules with biodynamic 
potentials. 
Fluorine has become an essential tool in drug discovery, including fluorine 
atom in potential medicines can have a variety of dramatic effects on the molecular 
properties perhaps making them more selective, increasing efficacy. Hence the           
3-chloro, 4-fluoro aniline was selected as starting molecule to synthesize 
fluorobenzothiazole incorporated with 1,3,4 – thiadiazole.    
 3-chloro 4-fluoro-aniline reacted with potassium thiocynate in the presence of 
glacial acetic acid and bromine at 0° C to give the corresponding 2-amino-6-fluoro-7-
chloro-(1,3)- benzothiazole,  which further reacts with hydrazine hydrade, ammonia, 
carbon disulphide, sodium chloroacetate in the presence of ethanol to form 2-
thiosemicarbazide substituted 6-fluoro-7-chloro-(1,3)-benzothiazole. The third step 
involves acyclation of 2-thiosemicarbazide followed by dehydrative cyclization using 
phosphorous oxy chloride to form 1,3,4 thiadiazole moiety, in this step different 
aromatic acids were also substituted. Then the 1,3,4 thiadiazole substituted compound 
was treated with ortho and para nitro anilines, in the presence of DMF to obtain 
different fluorobenzothiazole incorporated 1,3,4 thiadiazole compounds. The purity of 
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the synthesized compounds was checked by thin layer chromatography (Rf) and 
determining melting point. 
 The structure of the synthesized compounds were established by spectral (IR,           
1H NMR and Mass) analysis data. In SH1, the NH band at 3228 cm-1 and NH proton 
signal δ 4.0 of 2-amino benzothiazole in IR and 1H NMR spectrum respectively 
confirmed the formation of benzothiazole nucleus. In SH2, three protons singlet at δ 
2.0 and one proton singlet at δ 4.0 confirmed the formation of thiosemicarbazide 
group. 
In the compounds SH3, SH4, SH5 C = N band (1653 – 1632 cm-1) and C – S 
band (645 - 642 cm-1) of IR spectrum conforms the formation of 1,3,4 thiadiazole 
nucleus. In SH3, two doublets at δ 6.3 and one doublet proton at δ 7.4 indicates the 
formation of furan ring. In SH4, three doublet protons at δ 8.85, δ 7.97, δ7.44 and one 
singlet proton at δ 8.81 conforms the formation of an aromatic nucleus. In the case of 
SH5, two triplets at δ 6.97, 6.68 and two doublet at δ 7.23, 6.52 indicates the 
formation of an aromatic nucleus.  
The presence of nitro group in SH6-SH11 was ascertained from strong bands at 
(1584 -1510 cm-1) and (1365-1335 cm-1) corresponding to asymmetric and symmetric 
O=N=O stretching respectively. The C – Cl stretching band which appeared at SH1-
SH5 at (809 – 683cm-1) was disappeared in SH6-SH11. Instead, C – N stretching band 
appeared at (1346.02-1255.90cm-1) in SH6-SH11 indicated the attachment of ortho 
nitro aniline (or) and para nitro aniline group. 
In compounds SH6, SH8, SH10, two doublet for 2 protons (δ 8.20, δ 7.17- 
δ7.46) and two triplet protons at  (δ 7.68, δ 7.60) confirmed the presence of nitro 
group at ortho position in the aromatic ring. In compounds SH7, SH9. SH11 two 
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doublet protons at (δ 7.26- δ 7.34, δ 8.03 - δ 8.04) confirmed the presence of nitro 
group at para position in aromatic ring. 
In the Mass spectrum, synthesized compounds produced (M+) Molecular ion 
peaks at  351.12, 362.21, 376.16, 454.45, 454.45, 463.48, 463.48, 479.51 and 479.51 
values for SH3, SH4, SH5,SH6, SH7, SH8, SH9, SH10,and SH11 respectively, 
corresponds to their molecular formulas. The predicted chemical structure of titled 
compounds was further supported by the fragmentation peaks.  
 All the compounds showed very good antibacterial and antifungal activity even 
at less concentration. From the data, it is evident that the compound SH6 and SH8 was 
the most potent candidate against Micrococcus leutus and Proteus vulgaris in the 
anti-bacterial studies and compound SH11 was the much potent candidate against 
Aspergillus flavus in the antifungal studies. Since a fewer species have been used in 
this study, it was warranted to screen these compounds with varied species and 
resistant strains.   
 The anti-inflammatory activity confirmed that the test compound SH11 showed 
superior activity in the inhibition of oedema than SH8. However, both the test 
compounds were found to less activity than the standard drug. 
These results suggest that the tested compounds of fluorobenzothiazole 
incorporated with 1,3,4 thiadiazole have excellent scope for further development as 
commercial antimicrobial and anti-inflammatory agents. Further experiments were 
needed to elucidate their exact mechanism of activity. 
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